Study of Oxytocin in Autism to improve Reciprocal Social Behaviors
(SOARS-B)

NCT01944046

Protocol Number 111604-3
Protocol Version: 6.0

Sponsored by the Eunice Kennedy Shriver Institute for Child Health and Human Development
Under
Cooperative Agreement 1U01HD073984-01

Linmarie Sikich, MD — Lead Principal Investigator
Associate Professor, Department of Psychiatry and Behavioral Sciences, Division of Child and
Family Mental Health
Duke University Duke Center for Autism and Brain Development

Alexander Kolevzon, MD – Site Principal Investigator
Mount Sinai School of Medicine
Christopher McDougle, MD – Site Principal Investigator
Lurie Center for Autism, Massachusetts General Hospital
Jeremy Veenstra-VanderWeele, MD, PhD – Site Principal Investigator
Columbia University
Zachary Warren, PhD – Site Co-Principal Investigator
Vanderbilt University
Kevin Sanders, MD – Site Co-Principal Investigator
Vanderbilt University
Bryan King, MD – Site Principal Investigator
Seattle Children’s Hospital Research Institute
Russ Dean, MS – Data Center Principal Investigator
The University of North Carolina at Chapel Hill, Department of Psychiatry
Simon Gregory, PhD – Genetics Center Principal Investigator
Duke University

Katerina Tsilou, MD, Scientific Collaborator, NICHD
Alice Kau, PhD, Program Officer, NICHD

Cheryl Alderman, BS, CCRP, Project Manager
STATEMENT OF COMPLIANCE

This study will be carried out in accordance with Good Clinical Practice (GCP) as required by the following (use applicable regulations depending on study location and sponsor requirements; samples follow):

- ICH E6; 62 Federal Register 25691 (May 9, 1997)
- NIH Clinical Terms of Award

All key personnel (all individuals responsible for the design and conduct of this study) have completed Human Subjects Protection Training.
SIGNATURE PAGE

The signature below constitutes the approval of this protocol and the attachments, and provides the necessary assurances that this trial will be conducted according to all stipulations of the protocol, including all statements regarding confidentiality, and according to local legal and regulatory requirements and applicable US federal regulations and ICH guidelines.

*Site Investigator: ________________________________ (name)

Signed: __________________________________________ Date: ________________

* The protocol should be signed by the clinical site investigator who is responsible for the day to day study implementation at his/her specific clinical site; i.e., if Investigational New Drug (IND) study, the individual who signs the Form FDA 1572.
TABLE OF CONTENTS

Statement of Compliance ................................................................................................................. 2
Signature Page .................................................................................................................................. 3
Table of Contents ............................................................................................................................. 4
Protocol Summary ........................................................................................................................... 7
Key Roles ......................................................................................................................................... 8
1 Introduction: Background Information and Scientific Rationale ........................................ 10
   1.1 Background Information ........................................................................................... 10
   1.2 Rationale ................................................................................................................... 10
   1.3 Potential Risks .......................................................................................................... 13
2 Objectives .................................................................................................................................... 17
   2.1 Specific Aims ............................................................................................................ 17
   2.2 Study Outcome Measures ......................................................................................... 18
      2.2.1 Primary Outcome Measures ........................................................................ 18
      2.2.2 Secondary Outcome Measures ...................................................................... 19
      2.2.3 Additional Exploratory Outcome Measures ................................................. 19
3 Study Design ................................................................................................................................. 20
4 Study Enrollment and Withdrawal .......................................................................................... 21
   4.1 Subject Inclusion Criteria ......................................................................................... 21
   4.2 Subject Exclusion Criteria ........................................................................................ 21
   4.3 Rational for Exclusion and Inclusion Criteria .......................................................... 22
   4.4 Strategies for Recruitment and Retention ................................................................. 23
   4.5 Treatment Assignment Procedures ......................................................................... 24
      4.5.1 Randomization Procedures ........................................................................... 24
      4.5.2 Masking Procedures ...................................................................................... 25
5 Study Intervention/Investigational Product ........................................................................... 25
   5.1 Study Product Description ........................................................................................ 25
      5.1.1 Acquisition .................................................................................................... 25
   5.2 Dosage, Preparation and Administration of Study Intervention/Investigational Product .................................................................................................................. 25
      5.2.1 Suggested Titration .......................................................................................... 26
      5.2.2 Dose Deviations from Titration Schedule ....................................................... 26
      5.2.3 Weaning the Dose at Completion of Trial ....................................................... 26
      5.2.4 Interrupting Dose ............................................................................................. 27
   5.3 Accountability Procedures for the Study Intervention/Investigational Product(s) ..... 28
   5.4 Assessment of Subject Compliance with Study Intervention/Investigational Product .................................................................................................................. 28
5.5 Blinding/Unblinding ........................................................................................................28
5.6 Concomitant Medications/Treatments ........................................................................29

6 Schedule of Events ...........................................................................................................30
6.1 Screening .....................................................................................................................31
6.2 Randomized Double-Blind Treatment Phase: Oxytocin or Placebo (week 0-24) ....32
6.3 Open-Label Treatment Phase ....................................................................................36
6.4 Follow-Up Phase .........................................................................................................31
6.5 Early Termination Visit .............................................................................................41
6.6 Unscheduled/Re-Evaluation Visit .............................................................................42
6.7 Unscheduled Assessments ........................................................................................42
6.8 Interrupted Treatment Assessments ..........................................................................43

7 Study Procedures/Evaluations .........................................................................................43
7.1 Study Evaluations ......................................................................................................43
7.2 Laboratory Evaluations .............................................................................................47
7.2.1 Clinical Laboratory Evaluations ...................................................................47
7.2.2 Duke Genetics ...............................................................................................47
7.2.3 NIMH Genetic Repository (Optional) ..........................................................48

8 Assessment of Safety .....................................................................................................48
8.1 Adverse Events ..........................................................................................................48
8.1.1 TEAS .............................................................................................................48
8.1.2 Suicidality Assessment ...............................................................................49
8.2 Reportable Events .....................................................................................................50
8.2.1 Adverse Events .............................................................................................50
8.2.2 Unanticipated Problems ............................................................................50
8.2.3 Pregnancy .....................................................................................................51
8.2.4 Serious Suicidal Ideation ............................................................................51
8.2.5 Alert Lab/EKG Values ...............................................................................51
8.3 Reporting Procedures ............................................................................................51
8.3.1 Treatment Sites Reporting to Duke ..........................................................51
8.3.2 Duke Reporting Requirements to Other Regulatory Bodies ....................52
8.4 Stopping Procedures ..............................................................................................53
8.5 Safety Oversight .......................................................................................................53
8.5.1 Independent Medical Monitor .....................................................................53
8.5.2 Data Safety Monitoring Board (DSMB) ...................................................53
8.5.3 Overall Study Stopping Criteria ...............................................................54
8.5.4 Cardiac Monitoring Plan ...........................................................................54

9 Clinical Monitoring ........................................................................................................54
9.1 Site Monitoring Plan ..............................................................................................54

10 Statistical Considerations ...........................................................................................55
10.1 Statistical Analysis ...............................................................................................55
10.2 Sample Size Considerations ...............................................................................56

11 Subject Confidentiality .................................................................................................56
PROTOCOL SUMMARY

Title: Study of Oxytocin in Autism to improve Reciprocal Social Behaviors

Synopsis: This Phase 2 study will evaluate oxytocin as a supplemental treatment for improving social difficulties in individuals with autism.

Objectives: We will randomly assign 300 individuals between the ages of 3 - 17 years old with an autism spectrum disorder to 24 weeks of treatment with oxytocin or a matched placebo across six sites in the United States. Subsequently all participants will receive open-label oxytocin for 24 additional weeks. Post-treatment assessments will be done ~4 weeks after treatment stops. We will also determine OXTR methylation status at baseline, 8 weeks, 24 weeks and 36 weeks to explore potential relationships between OXTR methylation and baseline severity of social problems and/or treatment response.

Population: 300 subjects, male or female, ages 3-17 with an autism spectrum disorder

Phase: 2

Number of Sites: 6 treatment sites

Description of Agent or Intervention: Oxytocin, intranasal (8IU to 80IU daily)
Key Roles

Individuals: Overall Principal Investigator:
Linmarie Sikich, MD
Associate Professor
Associate Director
Duke Center for Autism and Brain Development
Duke University
Phone: (919) 681-0026
Email: linmarie.sikich@duke.edu

Medical Monitor:
Evdokia Anagnostou, MD
Child Neurologist
Clinician Scientist, Bloorview Research Institute
Assistant Professor, Department of Pediatrics
Phone: 416-753-6005
Fax: 416-753-6046
Email: eanagnostou@hollandbloorview.ca

Program Official:
Alice Kau, PhD
Program Officer
Eunice Kennedy Shriver Institute for Child Health and Development (NICHD)
Phone: 301-496-1385
Fax: 301-496-3791
Email: kauaa@mail.nih.gov

Project Manager:
Cheryl Alderman, BS, CCRP
Clinical Research Manager
Duke Center for Autism and Brain Development
Duke University
Email: Cheryl.alderman@duke.edu
Treatment Centers:

Principal Investigators:
Bryan King, MD
Seattle Children’s Research Institute
Phone: 206-987-1837
Fax: 206-987-2246
Email: bryan.king@seattlechildrens.org

Christopher McDougle, MD
Lurie Center
Massachusetts General Hospital
Phone: 781-860-1700
Fax: 781-860-1766
Email: cmcdougle@partners.org

Jeremy Veenstra-VanderWeele, MD
Columbia University
Phone: 773-896-8640
Email: jeremy.vvw@gmail.com
Alex Kolevzon, MD
Mount Sinai School of Medicine
Phone: 212-659-9134
Fax: 212-659-8710
Email: alexander.kolevzon@mssm.edu

Kevin Sanders, MD
Vanderbilt University
Phone: 615-708-6368
Fax: 615-936-6614
Email: kevin.b.sanders@vanderbilt.edu

Principal Investigator:
Russ Dean, MS
Department of Psychiatry
University of North Carolina at Chapel Hill
Phone: 919-260-2279
Fax: 919-966-5811
Email: russell_dean@med.unc.edu

Genetics Center

Principal Investigator:
Simon Gregory, PhD
Duke University
Phone: 919-681-5535
Fax: 919-684-0928
Email: simon.gregory@duke.edu
1 INTRODUCTION: BACKGROUND INFORMATION AND SCIENTIFIC RATIONALE

1.1 Background Information
There is a tremendous unmet need for accessible treatments that address core symptoms of ASD and are safe for sustained use, especially for the population of nonverbal individuals who require the most intensive lifelong support. We have created the ACE SOARS Network to provide the infrastructure necessary to meet this need on an ongoing basis. Our initial clinical trial, described in this application, is SOARS-B (the Study of Oxytocin in ASD to improve Reciprocal Social Behaviors). SOARS-B will test a very promising potential treatment—intranasal oxytocin—for ASD’s fundamental social communication deficits in a large, highly generalizable group of verbal and nonverbal children. SOARS-B will also provide information about the regulation of DNA methylation and transcription of the oxytocin receptor gene (OXTR), as well as other genes relevant to oxytocin’s CNS activity, as a function of time and in response to oxytocin treatment. These data will fill a key gap in our understanding of oxytocin’s role in ASD and its ability to alter epigenetic modifications of OXTR.

1.2 Rationale

THE SOCIAL MOTIVATION MODEL OF ASD PATHOPHYSIOLOGY
Difficulties in social orienting are evident across auditory and visual modalities and across the lifespan in ASD (Dawson, Meltzoff et al. 1998; Dawson, Webb et al. 2004; Sasson, Turner-Brown et al. 2008; Whitehouse and Bishop 2008). Electrophysiologic studies have found that individuals with ASD can attend to social stimuli if instructed to do so, but that they do not do so spontaneously (Ceponiene, Lepisto et al. 2003). In contrast, typically developing individuals give preferential attention to social stimuli, processing them faster with greater brain activation in prefrontal cortex than nonsocial stimuli (Goren 1975; Greene, Colich et al. 2011). Youth with ASD show slower processing of social versus nonsocial stimuli and the rate inversely correlates with the magnitude of social impairments (Dawson, Webb et al. 2004). Individuals with ASD also appear to experience reduced relative rewards from interpersonal interactions. In contrast to their typically developing peers, children with ASD prefer looking at pictures of inanimate objects to looking at pictures of people (Sasson, Turner-Brown et al. 2008; Sasson, Elison et al. 2011). They also fail to activate the ventral striatum, which is the center of the brain’s reward circuit, in response to social rewards whereas high levels of activation are evoked by social rewards in typically developing children (Scott-Van Zeeland, Dapretto et al. 2010). Further, when presented with social stimuli, children with ASD show reduced rather than increased activity in the prefrontal cortex, which assesses the relative value of a reward (Greene, Colich et al. 2011). The extent of reduction correlates with the severity of social and communication impairments in children with ASD (Dawson, Meltzoff et al. 1998; Ohnishi, Matsuda et al. 2000). These differences, as well as ASD’s clinical presentation, have led to the hypothesis that ASD is related to a fundamental impairment in social motivation (Waterhouse, Fein et al. 1996; Dawson, Carver et al. 2002; Grelotti, Gauthier et al. 2002; Dawson, Webb et al. 2005).

THE ROLE OF OXYTOCIN IN SOCIAL BEHAVIOR
Oxytocin is the brain’s most abundant neuropeptide. It can act as a classical neurotransmitter, a neuromodulator and a hormone with actions throughout the body (Gimpl and Fahrenholz 2001; Baskerville and Douglas 2010; Veening, de Jong et al. 2010). Oxytocin’s half-life in the plasma
is 1-2 minutes compared to ~30 minutes in the CSF. Central release of oxytocin is dependent upon CD38 and dramatically stimulates further release of oxytocin (~1000 fold) and increases the number of oxytocin-containing cells in the periventricular nucleus. Together these factors lead to long lasting oxytocin elevations throughout the brain following acute increases in CSF oxytocin. One of oxytocin’s major central actions is to activate the brain’s reward circuit by increasing dopamine release from the ventral tegmental area to the ventral striatum, amygdala and hippocampus. Its neuromodulatory actions appear to result primarily from somatodendritic release with binding to oxytocin receptors that are widely distributed throughout the limbic region and prefrontal cortex. Differential species-specific patterns of social behavior appear related to the distribution and density of oxytocin and vasopressin receptors in the brain. Oxytocin can bind vasopressin receptors, although it is unknown to what extent it does so normally. Oxytocin also can increase expression of oxytocin and vasopressin receptors in the brain although these effects are often sexually dimorphic and highly regulated by hormones and interleukins (Moos, Poulain et al. 1989; Tribollet, Charpak et al. 1989; Miyan, Nabiyouni et al. 2003; Morris and Ludwig 2004; Bales, Plotsky et al. 2007; Bales, van Westerhuyzen et al. 2007; Carter 2007; Carter, Boone et al. 2009). Social isolation and social stress somewhat later, during the post-weaning period, also have sexually dimorphic effects on the number of oxytocin and vasopressin neurons (Bales, Lewis-Reese et al. 2007; Tanaka, Osako et al. 2010).

In animal models including primates, oxytocin has been demonstrated to increase eye contact, social approach, social recognition, social memory, and generosity and to reduce stress responses (Takayanagi, Yoshida et al. 2005; Liu, Lopatina et al. 2008; Insel 2010). Oxytocin also influences social behavior in people(Macdonald and Macdonald 2010). Exogenous oxytocin increases gaze to eye regions, social cognition, social memory, positive communication, empathy, perceptions of trustworthiness, and cooperation within one’s own group (Kosfeld, Heinrichs et al. 2005; Zak, Kurzban et al. 2005; Domes, Heinrichs et al. 2007; Zak, Stanton et al. 2007; Baumgartner, Heinrichs et al. 2008; Guastella, Mitchell et al. 2008; Petrovic, Kalisch et al. 2008; Savaskan, Ehrhardt et al. 2008; Unkelbach, Guastella et al. 2008; Di Simplicio, Massey-Chase et al. 2009; Ditzen, Schae et al. 2009; Keri, Kiss et al. 2009; Rimmele, Hediger et al. 2009; Theodoridou, Rowe et al. 2009; De Dreu, Greer et al. 2010; Fischer-Shofty, Shamay-Tsoory et al. 2010; Guastella, Einfeld et al. 2010). Intranasal oxytocin also reduces cortisol; perceived stress, amygdala activation to threatening social images, and tolerance of ethnic differences (Heinrichs, Baumgartner et al. 2003; Kirsch, Esslinger et al. 2005; Petrovic, Kalisch et al. 2008; De Dreu, Greer et al. 2010; De Dreu, Greer et al. 2011). However, some of these effects, including enhancement of social memories and secure attachment, may be limited to individuals with less robust prosocial behaviors initially (Buchheim, Heinrichs et al. 2009; Bartz, Zaki et al. 2010; Bartz and Plantadosi 2010). Allelic variations in OXTR have also been correlated with infant attachment, social auditory processing, empathy and prosocial decision making (Lerer, Levi et al. 2010; Chen, Barth et al. 2011; Tops, van IJzendoorn et al. 2011).

**Oxytocin’s Potential Role in ASD**

Multiple variations in the oxytocin signaling system have been associated with ASD relative to controls. Allelic variations in the CD38 gene, which is required for central release of oxytocin, and in OXTR have been identified, some of which also have been correlated with cognition and functioning in individuals with ASD (Green, Fein et al. 2001; Wu, Jia et al. 2005; Jacob, Brune et al. 2007; Yrigollen, Han et al. 2008; Andari, Duhamel et al. 2010; Lerer, Levi et al. 2010; Liu, Kawamura et al. 2010; Munuesa, Yokoyama et al. 2010; Tansey, Brookes et al. 2010; Wermter, Kamp-Becker et al. 2010; Campbell, Datta et al. 2011; Riebold, Mankuta et al.
Modestly greater (~ 20-40%) OXTR methylation relative to controls has been found in two small, independent ASD samples (Gregory, Connelly et al. 2009). Reduced plasma oxytocin and CD38 mRNA expression have also been reported in ASD (Modahl, Green et al. 1998; Jin, Liu et al. 2007).

Oxytocin has shown promise for modifying social behavior in mouse models for ASD and in people with ASD and related disorders. In the Otxr null mouse, a single dose of oxytocin improved social deficits, reduced aggression and reduced vulnerability to drug-induced seizures, apparently acting through the vasopressin 1A receptor. Further, in these mice, repeated doses of oxytocin improved reversal learning, indicating enhanced cognitive flexibility (Sala, Braida et al. 2011). A single dose of oxytocin also improved social deficits in Cd38 null mice (Higashida, Lopatina et al. 2010). In Fragile X, which is frequently comorbid with ASD, oxytocin improved gaze avoidance and reduced cortisol elevations elicited by social interaction (Hall, Lightbody et al. 2012). In high functioning individuals with ASD, single doses of oxytocin enhanced attention to faces and eyes, visual and auditory affect recognition, the ability to distinguish whether others were being cooperative, and preference for interacting with receptive individuals (Hollander, Bartz et al. 2007; Andari, Duhamel et al. 2010; Guastella, Einfeld et al. 2010).

Oxytocin challenge also reduced self-reported compulsive and repetitive behaviors (Hollander, Phillips et al. 2003). Sustained oxytocin treatment has been reported to improve ASD symptoms in one child (Munesue, Yokoyama et al. 2010). In the only pilot study of sustained oxytocin treatment currently completed, affect recognition accuracy improved three times as much with 6 weeks of oxytocin treatment as had been reported in Andari’s single dose study (Anagoustou in preparation, network preliminary data). An 8-week blinded study of oxytocin in 24 children with ASD has been completed at UNC.

**OUR WORKING MODEL**

The above evidence regarding impairments in social orienting and social reward in ASD, oxytocin’s role in social orienting and social motivation, and variability in various aspects of oxytocin signaling among people with ASD, together with extensive preliminary evidence that supplemental oxytocin can impact social behaviors in ASD, have led to the formulation of our working model (Figure 1). We postulate that ASD pathophysiology acts to fundamentally alter social orienting and decrease the relative value ascribed to social rewards resulting in limited social motivation. Reduced social motivation leads to a vicious cycle of reduced social opportunities, reduced learning from social feedback, reduced skills and functional abilities and worsening of ASD’s core social communication symptoms, which further reduces social motivation. We hypothesize that sustained intranasal oxytocin treatment will positively modify the earliest parts of this cycle – social orienting and the value of social rewards – and disrupt the cycle leading to improvements in the core social and communication impairments of ASD.
### 1.3 Potential Risks

There is limited information about the safety of sustained use of oxytocin, although more information is emerging on a daily basis. Indeed, the objective of specific Aim 2 is to provide such information, gathered prospectively in a systematically elicited fashion.

Oxytocin has been reported to exert a large number of effects in the body and the brain (Gimpl & Fahrenholz 2001). The classic physiological effects of oxytocin in humans as well as all placental mammals are uterine contractions and milk ejection. These are conclusively known to occur only under the hormonal conditions at the end of pregnancy and postpartum when oxytocin receptors proliferate in the uterus and mammary tissue and lactogenesis occurs. Theoretically, oxytocin administration could cause uterine contractions during phases of the menstrual cycle when estrogen levels are relatively high or in women who are receiving estrogen. This, however, has never been demonstrated or reported. IV administration of Oxytocin is FDA approved for induction or facilitation of labor and postpartum contraction of the uterus. Intranasal oxytocin spray is also available in other countries to facilitate nursing in new mothers. Intranasal oxytocin also was FDA approved as a lactation aid in the United States until 1995 when it was withdrawn from the US market by the company that manufactured it, Novartis. This was a business decision and the FDA has confirmed no safety concerns were involved in this decision.

A number of adverse effects have been reported in the context of these two clinical applications, primarily with intravenous administration of oxytocin, which include anaphylactic reaction, hypertension, hypotension, cardiac arrhythmias, nausea and vomiting, afibrinogenemia and associated bleeding and, in the context of prolonged intravenous administration of oxytocin, hyponatremia. There has also been at least one report of life-threatening anaphylaxis during surgery when multiple drugs were being intravenously infused simultaneously (D. Pant, et al, 2009). Symptoms that may result from anaphylaxis include generalized hives, itchiness, or flushing; crampy abdominal pain, diarrhea, and vomiting; a feeling of anxiety and impending
doom; swelling of the lips, tongue, throat resulting in shortness of breath, wheezes or stridor, and low oxygen; a drop in blood pressure that may result in a feeling of lightheadedness and loss of consciousness; reduced muscle tone with possible loss of bladder control; and, most seriously, coronary artery spasm may occur with subsequent myocardial infarction or cardiac dysrhythmia and possible death. There is also a case report of psychosis occurring during oxytocin treatment of a man with obsessive compulsive disorder (Ansseau, Legros et al. 1987), although there are two completed pilot studies in schizophrenia that have reported reduction of psychotic symptoms(Feifel, Macdonald et al. 2010) – using a TDD of 40 IU during week 1, followed by a TDD of 80 IU for 2 weeks in 16 people; (Pedersen, Gibson et al. 2011) using TDD 48 IU for 2 weeks in 7 people) with no significant adverse events. There are a limited number of published, sustained oxytocin treatment studies in adults with other diseases (Denboer and Westenberg 1992) (Epperson, McDougle et al. 1996; Epperson, McDougle et al. 1996)(Den Boer 1992, Epperson 1996a, Epperson 1996b, none of which report significant adverse effects.

Evidence for safety of sustained intranasal oxytocin treatment in ASD

Placebo controlled safety data of sustained intranasal oxytocin treatment in people with ASD is available from one adult study (Anagnostou, Soorya et al. 2012) and two currently unpublished trials:

- the Anagnostou adult study (10 on TDD 48 IU oxytocin for 6 weeks, 9 on placebo),
- a trial conducted by Adam Guastella, personal communication 2012 (26 teens on total daily dose [TDD] 24 IU oxytocin for 8 weeks, 24 on placebo), and
- the UNC Autism Speaks pilot trial in 3-17 year olds (12 on oxytocin with TDD ranging between 4 IU and 64 IU for 8 weeks and 13 on placebo) and 24 on open label oxytocin TDD up to 48 IU for 8 weeks.

Adverse events observed during the double blind and open-label phases of the UNC oxytocin pilot study are shown in Table 1. Pink shading indicates events that were numerically more common in the oxytocin group than the placebo group. Green shading indicates events that were numerically more common in the placebo group. We also have been able to access the raw adverse event data from the two non UNC trials and have aggregated it to provide adverse event data on 48 individuals with ASD exposed to oxytocin for at least 6 weeks and 46 individuals with ASD treated with placebo. This aggregation, shown in Table 2, found low rates of adverse events in both oxytocin and placebo groups and no signal for greater adverse events with oxytocin treatment. None of these studies identified any significant or systematic changes in electrolytes or vital signs. The apparently higher rates in the UNC Pilot study probably reflect differences in the methods of assessing adverse events. The UNC pilot study used systematic elicitation of adverse events (same instrument as proposed for SOARS-B trial) and the other studies used spontaneous report or much more limited questionnaires.
Table 1. Treatment Emergent Adverse Effects in UNC Pilot study of children with ASD (subjects ages 3 -17 years old)

<table>
<thead>
<tr>
<th>Events of Moderate or Severe Intensity (Treatment Emergent)</th>
<th>8 Weeks OXYTOCIN Emergent by week 8</th>
<th>8 Weeks PLACEBO Emergent by week 8</th>
<th>16 Weeks OXYTOCIN Emergent b/w weeks 8-16</th>
<th>8 Weeks PLACEBO + 8 Weeks OXYTOCIN Emergent b/w weeks 8-16</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diarrhea</td>
<td>2 (16.7%)</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Allergies</td>
<td>1 (8.3%)</td>
<td>0</td>
<td>1 (9.1%)</td>
<td>1 (7.7%)</td>
</tr>
<tr>
<td>Mood Lability</td>
<td>1 (8.3%)</td>
<td>1 (7.7%)</td>
<td>1 (9.1%)</td>
<td>3 (23.1%)</td>
</tr>
<tr>
<td>Weight Increased</td>
<td>1 (8.3%)</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Insomnia, Initial</td>
<td>3 (25.0%)</td>
<td>2 (15.4%)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Insomnia, Mid/ Terminal</td>
<td>3 (25.0%)</td>
<td>2 (15.4%)</td>
<td>1 (9.1%)</td>
<td>0</td>
</tr>
<tr>
<td>Agitation</td>
<td>2 (16.7%)</td>
<td>1 (7.7%)</td>
<td>1 (9.1%)</td>
<td>1 (7.7%)</td>
</tr>
<tr>
<td>Aggression or Hostility</td>
<td>1 (8.3%)</td>
<td>4 (30.8%)</td>
<td>1 (9.1%)</td>
<td>1 (7.7%)</td>
</tr>
<tr>
<td>Anger/ Irritability</td>
<td>1 (8.3%)</td>
<td>3 (23.1%)</td>
<td>1 (9.1%)</td>
<td>3 (23.1%)</td>
</tr>
<tr>
<td>Oppositional</td>
<td>2 (16.7%)</td>
<td>3 (23.1%)</td>
<td>1 (9.1%)</td>
<td>2 (15.4%)</td>
</tr>
<tr>
<td>Low frustration tolerance</td>
<td>1 (8.3%)</td>
<td>2 (15.4%)</td>
<td>0</td>
<td>1 (7.7%)</td>
</tr>
<tr>
<td>↓ Attention/ Concentration</td>
<td>1 (8.3%)</td>
<td>2 (15.4%)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Accidental Injury</td>
<td>1 (8.3%)</td>
<td>2 (15.4%)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Hyperactivity</td>
<td>0</td>
<td>1 (7.7%)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Apathy</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1 (7.7%)</td>
</tr>
<tr>
<td>Rituals/ Repetitive Behaviors</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1 (7.7%)</td>
</tr>
</tbody>
</table>

Table 2. Aggregated adverse events with sustained intranasal oxytocin treatment in ASD

<table>
<thead>
<tr>
<th>Adverse Events</th>
<th>6-8 Weeks Oxytocin (n=48)</th>
<th>Placebo (n=46)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Increased Allergies</td>
<td>6%</td>
<td>2%</td>
</tr>
<tr>
<td>Nausea</td>
<td>6%</td>
<td>2%</td>
</tr>
<tr>
<td>Insomnia</td>
<td>6%</td>
<td>4%</td>
</tr>
<tr>
<td>Vomiting</td>
<td>4%</td>
<td>2%</td>
</tr>
<tr>
<td>Shortness of Breath</td>
<td>4%</td>
<td>2%</td>
</tr>
<tr>
<td>Agitation</td>
<td>2%</td>
<td>0</td>
</tr>
<tr>
<td>Absence Seizure</td>
<td>8%</td>
<td>17%</td>
</tr>
<tr>
<td>Increased Thirst</td>
<td>8%</td>
<td>11%</td>
</tr>
<tr>
<td>Increased Urination</td>
<td>2%</td>
<td>9%</td>
</tr>
<tr>
<td>Aggression</td>
<td>2%</td>
<td>9%</td>
</tr>
<tr>
<td>Fatigue</td>
<td>0</td>
<td>4%</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>4%</td>
<td>7%</td>
</tr>
<tr>
<td>Lightheaded</td>
<td>4%</td>
<td>7%</td>
</tr>
<tr>
<td>Oppositionality</td>
<td>4%</td>
<td>7%</td>
</tr>
<tr>
<td>Mood Lability</td>
<td>0</td>
<td>2%</td>
</tr>
<tr>
<td>Symptom</td>
<td>Incidence</td>
<td>Risk</td>
</tr>
<tr>
<td>------------------------------</td>
<td>-----------</td>
<td>------</td>
</tr>
<tr>
<td>Cough</td>
<td>0</td>
<td>2%</td>
</tr>
<tr>
<td>Rash</td>
<td>0</td>
<td>2%</td>
</tr>
<tr>
<td>Increased anxiety/Panic attack</td>
<td>0</td>
<td>2%</td>
</tr>
<tr>
<td>Increased social withdrawal</td>
<td>0</td>
<td>2%</td>
</tr>
<tr>
<td>Increased tics</td>
<td>0</td>
<td>2%</td>
</tr>
<tr>
<td>Increased Appetite</td>
<td>0</td>
<td>2%</td>
</tr>
<tr>
<td>Decreased Appetite</td>
<td>6%</td>
<td>7%</td>
</tr>
<tr>
<td>Headache</td>
<td>6%</td>
<td>7%</td>
</tr>
<tr>
<td>Irritability</td>
<td>2%</td>
<td>2%</td>
</tr>
<tr>
<td>Decreased Attention</td>
<td>2%</td>
<td>2%</td>
</tr>
<tr>
<td>Increased Restlessness</td>
<td>2%</td>
<td>2%</td>
</tr>
<tr>
<td>Disinhibition</td>
<td>2%</td>
<td>2%</td>
</tr>
<tr>
<td>Low Frustration Tolerance</td>
<td>2%</td>
<td>2%</td>
</tr>
<tr>
<td>Increased Crying</td>
<td>2%</td>
<td>2%</td>
</tr>
</tbody>
</table>

There is also preliminary safety data regarding even more extended oxytocin treatment for up to 6 months in children with ASD available by personal communication from an ongoing trial funded by the US Department of Defense being conducted by Evdokia Anagnostou in 11 youth 10-17 years treated for up to 6 months treated with oxytocin. There have been no significant lab abnormalities in these participants. Three (14%) have shown increases in irritability or mood lability and one has had increased allergy symptoms.

**Blood Draw Risks:**
During laboratory blood draws the risks involved are pain, bruising, and rarely, infection at the location where the blood was taken. This risk will be minimized by having a trained professional take each participant’s blood. We will attempt to avoid these risks by using aseptic techniques, and applying pressure after the phlebotomy. A local anesthetic may be used to reduce associated pain if the participant wishes to use it. If a subject becomes nervous or agitated about the phlebotomy procedures, we will utilize an anti-anxiety medication to calm subjects who may be nervous.

**Psychological/Psychiatric Risk:**
This patient population can be at risk for worsening of psychiatric/psychological symptoms that may be attributed to their mental illness alone, medication non-adherence, or a number of other causes that may not be related to this study. The Principal Investigator will use clinical judgment to assess each treatment emergent adverse event and determine intensity and relatedness to the study. In cases of worsening of symptoms patients may require inpatient hospitalization. If the study doctor feels that the subject is at serious risk for hurting themselves or others, he/she can ask a judge to allow the participant to be hospitalized against his/her will. Subjects may become frustrated during study procedures. Research staff will work to ensure that all directions and questions are easy to understand for subjects who have intellectual difficulties. Subjects will be allowed breaks, if needed.

Since this is a large trial of oxytocin that will require patient involvement for up to 52 weeks (1 year), it is suggested that a subject’s psychiatric care will be assumed by the study physician. However, this can be determined by site as some institutions have different regulations surrounding psychiatric care and research participation.
Confidentiality Risk
The potential indirect risks are related to loss of confidentiality and could include someone such as an insurance agency or employer learning that the participant has a serious mental illness with resulting potential stigmatization. It is also possible that public knowledge of this diagnosis or its documentation in the medical record could lead to inability to obtain insurance coverage at reasonable rates in the future.

Additional risk for biomarker/genetics portion:
There are no additional needle sticks for this portion of the study. However, the additive in the DNA collection tube can be irritating if it contacts the skin so special care will be taken so that, during the blood draw, the additive in the tube doesn’t flow out into the collection needle.

2 OBJECTIVES

The ACE SOARS Network’s immediate goals are to translate these exciting findings regarding oxytocin’s neurobehavioral effects into an evidence-based, widely accessible intervention for ASD’s fundamental impairments in reciprocal social behaviors and to identify factors that differentially influence response to oxytocin treatment in ASD. Our central hypothesis is that intranasal oxytocin will partially reverse the early pathophysiologic alterations in social orienting and the salience of social rewards present in ASD, which lead to decreased social motivation and ultimately to ASD’s core social communication impairments, thereby enhancing reciprocal social behaviors (see Figure 1, in Impact section). Sustained improvements in social motivation and social reciprocity are expected to facilitate communication and learning and ultimately improve functioning. We will accomplish our immediate goals by conducting SOARS-B, a large (n=300) randomized, double-blind trial of sustained (24 week treatment with intranasal oxytocin in children 3-17 years old with ASD and examining clinical and biological factors that may predict or enhance response. Regardless of SOARS-B’s outcome, its results will significantly impact the care of people with ASD by definitively testing a very promising translational treatment strategy in a highly generalizable sample. The moderator analysis is likely to support treatment personalization. The exploratory epigenetic studies will enhance understanding of the regulation of key biological pathways in ASD and facilitate development of future treatments.

2.1 Specific Aims

Specific Aim 1: Determine the efficacy of intranasal oxytocin treatment in children with ASD.
Analysis 1a: Compare oxytocin treatment to placebo for improving reciprocal social behaviors. Hypothesis: oxytocin will reduce maladaptive social behaviors and increase prosocial behaviors.
Analysis 1b: Compare oxytocin treatment to placebo for improving reciprocal social behaviors separately in subgroups of children who have significant language impairment and intellectual disability and those whose language and intellectual abilities are in the normal range at baseline. Hypothesis: oxytocin’s actions on the social reward system are unrelated to verbal or cognitive abilities.
Analysis 1c: Compare the treatments’ enhancement of social motivation, cognitive skills and functioning. Hypothesis: oxytocin will increase social motivation, improving acquisition of cognitive and functional skills.
Specific Aim 2: Provide information about the safety and tolerability of intranasal oxytocin.  
Analysis 2a: Compare incidence and severity of treatment emergent adverse effects, clinically significant laboratory and electrocardiogram changes, serious adverse events and treatment discontinuation due to tolerability issues over 24 weeks in the oxytocin and placebo groups.  
Analysis 2b: Tabulate these safety indicators during 24 weeks of open oxytocin treatment.

Specific Aim 3: Identify clinical or biological traits that preferentially influence response to oxytocin.  
Analysis 3a: Determine if baseline age influences behavioral changes more in the oxytocin group.  
Hypothesis: the magnitude of changes observed depends on both intervention efficacy and brain plasticity. Analysis 3b: Determine if baseline OXTR methylation levels predict level of behavioral improvement.  
Working hypothesis: greater OXTR methylation decreases oxytocin receptor density and increases the amount of oxytocin required to bind available receptors and elicit optimal reciprocal social behaviors.  
Analysis 3c: Determine if other baseline traits or intervening experiences interact preferentially with oxytocin.

Exploratory Aim 4: Describe the changes in OXTR methylation and mRNA expression of genes related to oxytocin signaling occurring over 24 weeks with oxytocin and placebo treatment.  
Rationale: understanding the regulation of oxytocin signaling will facilitate development of novel treatments.

2.2 Study Outcome Measures

2.2.1 Primary Outcome Measures

Our primary outcome is reciprocal social behaviors, which we will assess using two co-primary measures. The first measure is the ABC-SW subscale, which is being used in other clinical trials focusing on the core social and communication symptoms of autism. The other measure is the Sociability Factor (SF), a combined measure derived from 13 items of the ABC-SW, which primarily captures aloof, and avoidant behaviors, and the Pervasive Developmental Disorders Behavior Inventory-Screening Version (PDDBI-SV, Cohen 2011), a recently developed measure which assesses both maladaptive social problems and social skills. The PDDBI-SV is comprised of 18 items included in the older, more comprehensive Pervasive Developmental Disorders Behavior Inventory (PDD-BI, Cohen 2003). The PDDBI-SV assesses both social impairments typically associated with the active but odd subtype of ASD and development of pro-social skills that are integral to improved reciprocal social behavior. The PDDBI-SV results in a raw SOCDEF score, which is the sum of the reverse-scored social skills and the regularly-scored problems, and a SOCDEF T score. In marked contrast to the PDD-BI’s age-based standard scores (for children 1.5 and 12.5 years old), the PDDBI-SV SOCDEF score does not change with age in individuals with ASD. The PDDBI-SV has been validated in original PDD-BI development sample of 311 children 1-17 years old and a recently-acquired sample that includes 145 youth between 13 and 15 years old, 90 between 16 and 19 years, and 59 between 20 and 40 years (Cohen 2011, personal communication). The sociability factor SF will be calculated by discarding the three lethargy items from the ABC-SW (questions 3, 32, and 53,
which all assess reduced physical movement), summing the 13 remaining items of the ABC-SW subscale, and adding it to the PDDBI-SV raw SOCDEF score. The sociability factor SF is derived from two well-validated instruments and has face validity for capturing the full range of impairments in reciprocal social behaviors observed in ASD. We chose not to use the Social Responsiveness Scale (SRS), which was developed to provide a quantitative measure of social impairments typically observed in ASD in children 3-18 years old, because it has been demonstrated to be quite stable over time (Constantino, Przybeck et al. 2000; Constantino 2009) and no intervention studies have clearly demonstrated its sensitivity to change.

2.2.2 Secondary Outcome Measures

**Secondary Outcome Measures:** We will use the SRS Social Motivation subscale to assess oxytocin’s hypothesized mechanism of action. Cognitive skills will be assessed using the Stanford Binet-5th Edition (SB-5) (Roid 2003). If a child cannot complete the routing tests on the SB-5, they will be assessed using the Mullen. Functional skills including communication will be assessed using the standard score of the Vineland 2 adaptive behavior composite and all its subscales, the Caregiver Strain Questionnaire total and subscale scores (Brannan, Heflinger et al. 1997) and, in verbally fluent youth, a 7 item questionnaire being piloted to assess participant satisfaction with their social relationships, which is included in the appendix. The specific components of these measures tested in Aim 1c are SRS Social Motivation subscale, the NV IQ or Mullen Early Learning Composite standard score, and the Vineland Adaptive Behavior Composite. Other subscales of the ABC, Caregiver Strain Questionnaire and SRS measures will be analyzed in an exploratory way.

2.2.3 Additional Exploratory Outcome Measures

**Additional Clinical Assessments:** In order to provide a comprehensive assessment of the clinical features of children in the trial we will also perform several other assessments. The Clinical Global Impressions – Improvement (CGI-I) score, which is routinely used in pharmacologic clinical trials, will capture the study physician’s global impression of response. We will also incorporate a continuous visual analog scale of change in three key areas of overall functioning (similar basis for assessment as CGI-I), social communicative functioning, and repetitive behaviors and restricted interests that is rated with reference to the individual participant’s baseline characteristics. We will also incorporate the Reading the Mind in the Eyes Task (Baron-Cohen, Wheelwright et al. 2001) into our analysis, which has been shown to be sensitive to both single and sustained doses of oxytocin (Domes, Heinrichs et al. 2007). However, its use is restricted to high-functioning individuals who can verbally identify specific emotions. We will also obtain the other SRS-2 subscales to specifically assess its sensitivity to change in comparison to other outcomes. All concomitant medications and behavioral or alternative medication therapies will be recorded at each visit. Assessment of treatment-emergent adverse effects will utilize the systematic longitudinal adverse effects scale developed by Sikich and described in the oxytocin treatment section. We will also determine the reason for premature discontinuation of treatment and physician, caregiver judgment regarding the child’s treatment group.
**Biologic Outcome Measures:** We will obtain blood, urine and vital signs from participants at regular intervals in order to assess the safety of oxytocin. In addition, we obtain blood from participants at screening and weeks 8, 24 and 36 that will used to assess oxytocin levels, \( OTXR \) methylation status and to assess mRNA expression. We will obtain saliva at the same time points to perform salivary oxytocin levels. We will also determine whole blood serotonin at screening, weeks 8 and 24.

**Potential interacting factors:** We will assess potential environmental factors that may interact with oxytocin treatment through caregiver reports. We are particularly interested in social skills treatments, interventions the child receives outside of the school setting and social opportunities outside of school settings for interactions with peers, adults who are not caregivers/treatment providers, and caregivers/treatment providers. We will also examine potential interactions between antipsychotic treatment, stimulant treatment, \( \alpha \)-adrenergic treatment and oxytocin treatment.

### 3 Study Design

SOARS-B is a large (\( n = 300 \)) randomized, placebo-controlled trial of sustained (24 week), flexible dose intranasal oxytocin treatment in children 3 to 17 years old with ASD. The primary aim is to determine the efficacy of oxytocin for improving reciprocal social behaviors in the entire sample and the low- and high-functioning subgroups. Social motivation, cognitive skills and functional behaviors will be secondary outcomes. We will examine safety during the double-blind phase and the 24 week open extension phase. The second major aim of the study is to identify whether participant baseline clinical and biological characteristics such as age and extent of OXTR methylation preferentially influence response to supplemental oxytocin. In post-hoc exploratory analyses, we will examine the influence of intervening processes, such as concomitant antipsychotic or social skills treatments that are likely to be randomly distributed between the oxytocin and placebo groups, on oxytocin response. Finally, participants will be assessed approximately 4 weeks after the last dose of oxytocin (~week 53-55) to assess safety and follow up on any unresolved/continuing adverse events. The target dose will be 48/0 IU total daily dose (TDD), which will typically be achieved by week 8 during the blinded phase and week 28 in the open label phase according to a recommended titration schedule. However, doses will be flexible with slowing of the titration, alteration of the dosing administration times, reduction of dose and increases beyond the target dose (after 7 weeks of target dose treatment) allowed according to specific guidelines.
4 STUDY ENROLLMENT AND WITHDRAWAL

4.1 Subject Inclusion Criteria

- Be between the ages of 3 years 0 months and 17 years 11 months at the time of randomization
- Be diagnosed by clinician experienced in assessment of ASD with an autism spectrum disorder using DSM-5-TR criteria
- Have a clinical diagnosis of ASD confirmed either using the Autism Diagnostic Observation Scale-2 (ADOS-2) or the Autism Diagnostic Interview-Revised (ADI-R, Rutter, 2003). For subjects who do not meet criteria on either, but the clinician still believes to have ASD, those individuals may be included if the SC agrees.
- Have a guardian who is able to provide informed consent
- If cognitively able, subject must be able to provide informed assent/consent

4.2 Subject Exclusion Criteria

- Have a known diagnosis of Rett Syndrome or Childhood Disintegrative Disorder, or have marked sensory impairment such as deafness or blindness. Legal blindness is defined as a visual acuity of 20/200 or less and central visual field of 20 degrees or less with both eyes open. Profound deafness is defined as a flat audiogram.
- Have active cardiovascular disease or renal disease that is not controlled by medication
- Subjects who are pregnant, lactating, or who refuse to practice contraception if sexually active
- Subjects who have had changes in allied health therapies, behavioral or educational interventions within the two months prior to randomization other than those associated with school holidays
- Subjects who have had changes in psychiatric medications within 4 weeks of randomization
- Subjects who have had previous treatment with chronic intranasal oxytocin (daily dosing more than 1 month).
- Subjects who have caretakers who are unable to speak English, be consistently present at visits to report on symptoms, or are otherwise judged as unable to comply with the protocol by the data collection site team.
- Subjects with active seizures within the 6 months preceding screening or baseline.

4.3 Rationale for Inclusion and Exclusion Criteria

Frequently when large trials are done with a very specific subpopulation, no further studies are done to explore response in other subgroups because of the large cost of such trials and public frustration with studies perceived as duplicative and incremental. However, families and clinicians caring for individuals from untested subgroups often struggle to make treatment decisions without any specific evidence regarding efficacy or safety. Therefore, we have made the entry criteria for participation in this trial as broad and generalizable as possible. We will conduct secondary post-hoc analyses of various clinical and biological factors that might typically be excluded (e.g., concomitant antipsychotic treatment, Fragile X) instead. This approach will provide the greatest amount of clinically relevant information regarding sustained oxytocin treatment in the shortest amount of time possible.

We also will allow psychotropic medications with strong evidence of efficacy for treating problem behaviors or psychiatric disorders frequently associated with ASD (specifically antipsychotics, anticonvulsants, stimulants, and other medications approved for ADHD) to increase generalizability. We will allow agents that influence serotonergic neurotransmission or specifically impair reward pathways in the brain (e.g., naltrexone) in order to make the study results more generalizable to the actual autism population, ensure a diverse sample and increase recruitment. While there is minimal evidence to support efficacy in ASD symptoms, the truth is that community practitioners are prescribing these agents to children and adolescents with ASD.

We chose not to require a minimal baseline score on the Aberrant Behavior Checklist – social withdrawal subscale (ABC-SW, (Aman, Singh et al. 1985)) due to concerns this would exclude many people with ASD, even though such a threshold would increase comparability with an ongoing trial also targeting ASD’s core social behaviors and might increase the probability of observing ABC-SW changes. Also, diagnosis of ASD requires significantly impaired reciprocal social behavior.

We are including very young children because we believe they are likely to demonstrate significantly greater functional improvements than older children as a result of increased intervention services and greater brain plasticity. We believe that the careful titration schedule and close adverse effect monitoring, along with a dosing administration handout that staff will provide to participants, will provide sufficient safety for this vulnerable population. Further, the prospective, systematically elicited information about safety in young children gained in this study will inform the design of future trials and off label use in young children.

We are including children with low cognitive functioning because there is no rationale for believing that they would be less likely to respond to oxytocin treatment. Such children are seldom included in clinical trials and desperately need effective treatments to reduce their
suffering. We expect that we will still be able to measure social reciprocity which will be valuable in studying the effects of oxytocin on children with autism of varying cognitive functioning.

We will exclude subjects with non-English speaking caretakers because our staff is not qualified (i.e. they are not fluent in other languages) to explain the study to non-English speaking subjects. In addition, many of the pencil and paper assessments used to diagnose the included diagnoses have not been normed with non-English speaking populations. Thus, the measures may not be as appropriate, valid, and/or reliable for non-English speaking subjects.

We are excluding children who are deaf and blind because part of the outcome measures are child rated (i.e: reading in the mind’s eye and self-rating of social functioning). Children who are blind and/or deaf would not have reliable testing for these measures and therefore invalidate that data during analysis. If it is unclear if a subject is blind or deaf, we will refer them to an external provider for further testing prior to enrolling the subject.

We will exclude individuals who have uncontrolled seizures (i.e: seizure activity within the past 6 months prior to baseline or screening). This is an added safety measure to ensure that any individuals with seizures have them properly under control prior to randomization.

4.4 Strategies for Recruitment and Retention

Before the study is initiated, it will be approved by the Institutional Review Board (IRB) at each treatment site and the Network DSMB. All of the subjects and their parent/guardian will provide consent/assent for participation in this study. In addition to the informed consent requirements, per the Privacy Rule (HIPAA) regulations, research participants will provide a written “authorization” to use their Protected Health Information (PHI) in connection with research. In requesting an authorization from potential participants, investigators will specify how the information will be used and how the privacy of that information will be protected. The researcher obtaining Informed Consent will thoroughly review the consent form with the child and his or her parents, including study procedures and potential risks and benefits of study participation. The child and parents will be encouraged to ask questions throughout the process. It will be emphasized that research is voluntary and that the subject can opt out of this project at any time without jeopardizing his/her treatment. Participants who turn 18 during their participation in the study and who have the cognitive capacity to read and understand the consent form, and whose parents do not have legal guardianship of them, while participating in this study will be re-approached by one of the physician investigators. The investigator will continue the informed consent process acknowledging that the individual is now legally an adult and will ask the participant if they voluntarily wish to continue their participation in the study. If he/she does, the participant will be asked to sign the informed consent document and a new HIPAA authorization. If the individual does not wish to continue participation they will be withdrawn from study treatment just as any other individual who chooses to withdraw consent from participation.

This study will be registered in ClinicalTrials.gov no later than 21 days after the first subject is enrolled. Summary results information (including adverse events) will be reported no later than 1
year after the completion date for the study. Grant and progress report forms shall include a certification that the investigators have made all required submissions to ClinicalTrials.gov.

4.5 Treatment Assignment Procedures

4.5.1 Randomization Procedures

We expect to screen ~ 400 children in order to randomize 300. Individuals, who meet all inclusion criteria and none of the exclusion criteria, will be categorized by the data base according to the following criteria to determine if they belong in the high or low functioning stratum. Using a centralized, randomization scheme with permuted blocks of 4 or 6, stratified by functional status, the database will randomly assign the treatment which will be communicated to the site investigational pharmacy. Enrollment within the two strata will be monitored to ensure that there are at least 142 participants in each. Randomization will be further stratified by age so that at least 21% of the participants within each stratum fall into each of the specified age groups 3-6, 7-11, 12-17. The minimal representation of these age groups should ensure that the potential moderating effects of age can be fully assessed. We will not stratify by age due to the potential for very small cell sizes with large numbers of strata.

If a functional or age subgroup appears to be under represented after 50%, 75% and 90% of participants are randomized, recruitment efforts will be focused on the under-represented subgroups. Children will be considered low-functioning if they have significant language impairment and intellectual disability (NV IQ or Mullen Early Learning Composite Standard Score < 70). We define significant language impairment in participants 72 months or older, as having a lack of fluent phrase speech reflected by use of ADOS Module 1 or 2. In participants 5 years, 8 months or younger, significant language impairment will be defined as lack of phrase speech and Mullen receptive language subtest score more than 1 SD below the mean for age. Participants will be considered as high-functioning if they have nonverbal IQ ≥ 70 and significant language skills, which we define as fluent phrase speech reflected by use of ADOS Module 3 or 4, or, if 5 years, 8 months or younger, Mullen receptive language subtest score within 1 SD of the mean for age or higher. Participants who fail to meet both the language and cognitive criteria for low- or high-functioning will be stratified according to their language abilities, which more strongly predict long-term outcome (Venter, Lord et al. 1992; Szatmari, Bryson et al. 2003; Billstedt, Gillberg et al. 2005; Sallows and Graupner 2005).

Randomization Method: We will randomize centrally, using our data management system. The UNC Data Team is familiar with this process as they have done this in our multicenter IMPACT trial. When a site needs to randomize a subject, after baseline is assessed, the coordinator opens the Randomization form. This form uses already assessed strata to randomize from the appropriate stratum. We will not stratify by site. We felt that both functional status and age group were more likely to be related to the outcome than site, and there are limits to how many strata we can have. We will stratify by functional status (high or low) and age group (3 age groups), producing 6 strata. The unblinded statistician will generate a randomization plan for each of the 6 strata, using a permuted block algorithm with randomly selected block sizes of 2 and 4, using SAS. The table will be exported to an Excel file and sent to the data manager. This can be done without having the lead statistician ever actually see the randomization plan.
(He/She will debug the program and when debugged, run it with a new seed for the random number generator without seeing the results.) The database manager will import the randomization plan as a table in Access. The Randomization form will use Visual Basic code and the values of the strata variables to enter the correct subset of the table and choose the first unused treatment. It will generate an ID number and send an email to the appropriate pharmacy, where drug will be assigned.

4.5.2 Masking Procedures

The spray and a matched placebo solution containing all of the same ingredients except for oxytocin will be packaged in indistinguishable nasal administration bottles.

5 STUDY INTERVENTION/INVESTIGATIONAL PRODUCT

5.1 Study Product Description

Oxytocin contains the synthesized peptide oxytocin in a solution formulated to promote absorption through the nasal mucosa.

5.1.1 Acquisition

All the proper documentation regarding how the drug and placebo is compounded/manufactured will be submitted to the FDA as an amendment to the current IND (#111604) held by Dr. Linmarie Sikich for sustained intranasal oxytocin treatment in 3-17 year olds with autism.

5.2 Dosage, Preparation and Administration of Study Intervention/Investigational Product

Participants in the study will be randomly assigned to treatment with intranasal oxytocin or placebo. Participants or their caregivers will be taught to administer the nasal spray, alternating nostrils, by the study personnel. The caregivers will be provided with suggestions for how to encourage their children to comply with the procedure including setting up a fun routine and providing rewards. The caregivers will also be provided with a dosing handout to monitor subjects’ weekly dosing to ensure that participants are reaching their optimal dose. The study staff will fill in the dates at each visit and the dosing (if applicable). The target dose for the study is 48/0 IU total daily dose (TDD). The target dose will begin at the week 8/28 visit, unless issues with tolerance or compliance slow the recommended titration schedule. Every effort will be made to achieve the target dose of 48/0 IU TDD unless it is clear that the child cannot tolerate it.

5.2.1 Flexible Dose:

- In the blinded phase, dosing will be flexible between 8/0 IU TDD and, after the target dose (48 IU TDD) has been maintained for ~ 7-8 weeks, up to 80/0 IU TDD, to allow one to optimize dosing for the individual child in cases of intolerance or inadequate response. Doses will typically be given in two equal amounts in the AM and the PM, with the
maximal dose at any one time being 48/0 IU. If doses are uneven the larger dose should be given in the AM.

- In the open label phase, dosing will be flexible between 24 IU TDD and, after the target dose (48 IU TDD) has been maintained for ~7-8 weeks, the dose can be increased to 72 TDD at week 36. The preferences is for 24 IU TDD to be given in the AM, 48 IU TDD should be split equally between morning and PM dosing and 72 IU TDD should be split as 48 IU in the AM and 24 IU in the PM.

5.2.2 Suggested Titration to the Target Dose

- **Blinded Phase:** In the double-blind phase, titration to the target dose is expected to take 8 weeks and follow the suggested table below unless there are issues with tolerance or compliance. Dosing will begin at 8/0 IU in the AM at baseline. Typically, the dose will increase to 8/0 IU twice daily (BID) (16/0 IU TDD) at week 2. Dose will then be increased by 8/0 IU twice daily (BID) at weeks 4 and 8 with TDDs of 32/0 IU and 48/0 IU respectively. During the initial titration period (baseline to week 8), dosing increases should never occur before the time point specified in the schedule. Specifically one could not go to a TDD of 16/0 IU prior to week 2, or 32/0 IU prior to week 4 or 48/0 IU prior to week 8.

<table>
<thead>
<tr>
<th>Week 0</th>
<th>Week 2</th>
<th>Week 4</th>
<th>Week 8</th>
</tr>
</thead>
<tbody>
<tr>
<td>8 IU qD</td>
<td>8 IU BID</td>
<td>16 IU BID</td>
<td>(48 IU TDD)</td>
</tr>
<tr>
<td>(8 IU TDD)</td>
<td>(16 IU TDD)</td>
<td>(32 IU TDD)</td>
<td></td>
</tr>
</tbody>
</table>

- **Open Label Phase:** In the open-label phase, from week 24 to week 28, the dose will be 24 IU in AM for a TDD of 24 IU. From week 28-36 the dose will be 48 IU TDD (ie. 24 IU BID). At week 36 the dose can be increased to 72 IU TDD (ie. 48 IU in the morning and 24 IU in the afternoon).

<table>
<thead>
<tr>
<th>Week 24</th>
<th>Week 28</th>
</tr>
</thead>
<tbody>
<tr>
<td>(24 IU TDD)</td>
<td>(48 IU TDD)</td>
</tr>
</tbody>
</table>

5.2.3 Dose Deviations from Titration Schedule

- **Maintaining pre-target dose:**
  - In the blinded phase (week 0-24) If the child is having difficulty tolerating the medication or administration of the nasal spray during the initial dose titration phase, the clinician may choose to hold the dose at weeks 2, 4 or 8 rather than increasing per the titration suggestions. If dose is held, it may then be increased by 8/0 IU 1-2 x/day after assessment of the participant (phone/email or in person) between scheduled visits if desired in order to achieve the target dose of 24/0 IU twice daily or 48/0 IU total daily dose as close to the week 8 visit as possible.
  - In the open-label phase if the child is having difficulty tolerating the medication, the clinician may choose to hold the dose at 24 IU qD at week 28, 32, 36, 40, or 44.
• **Dosing Reductions:** All dosing reductions should be discussed with the site PI within 2 business days and reported to the lead site for discussion with other treatment site PIs.

  o **Mandatory Dose Reductions:** The dose must be reduced to the highest previously well tolerated dose *if any of the following criteria* are met AND the treating clinician is comfortable with the decrease. The dose may be reduced between appointments in the first two cases.
    - Clinician judges an AE to require immediate reduction of dose OR
    - CGI-I score is 6 or 7 OR
    - Two consecutive CGI-I scores at in person visits are worse than the preceding two CGI-I scores.
  
  If any of the three criteria are met, but the treating clinician is not comfortable with the decrease, the dose will be maintained until discussed with the all treating site PIs. The majority of the treating site PIs may determine that a mandatory decrease should be made.

  o **Optional Dose Reductions:**
    - In the blinded phase the dose may be reduced by 8/0 IU once or twice a day at any time at the clinician’s discretion due to a clinically significant adverse event, poor tolerability of dosing, parent request. The dose should not be subsequently increased without reassessing the participant by phone/email or in person. The dose can be increased between scheduled visits after clinical reassessment of the participant (phone, email or in person).SLAES and CGI-I to be completed at physician discretion. If SLAES is not completed, then adverse events must be assessed and documented.
    - In the open-label phase the dose may be reduced in 24 IU increments to a minimum dose of 24 IU every other day.

• **Dosing Increases Above Target Dose:**

  o **In the blinded phase** after the target dose has been maintained for at least 7 weeks the dose may be increased by 16/0 IU TDD only at each of the subsequent visits. Thus, at week 16, the maximal possible dose will be 64/0 IU TDD. However, at week 20 the dose could be increased to either 64/0 IU TDD if there had been no prior increase at week 16 or, could be increased to 80/0 IU TDD if the dose had been increased at week 16.

  o **In the open-label phase** after the target dose has been maintained for ~ 7-8 weeks then the dose can be increased (at week 36) to 72 IU TDD.

  o **Applies to both phases:** Increases past the target dose are NOT required and may ONLY be made if the following conditions are met
    - No evidence of clinically significant adverse events
    - Parents agree
    - Clinician agrees
5.2.4 Weaning Dose at Completion of Trial

- For 72 IU TDD at week 48 we would reduce dose to 24 IU BID for 1 week then 24 qAM and then 24 IU every other day in the morning for a week then stop.
- For 48 IU TDD at week 48 we would reduce to 24 IU every morning for a week and then reduce to 24 IU every other day for 1 week then stop.
- For 24 IU TDD at week 48 we would reduce to 24 IU every other day for 1 week then stop.
- For anything less than 24 IU TDD, no down titration is required.

For early terminations, attempts should be made to follow down titration as listed above. It will not be considered a deviation if families are non-compliant.

At week 53-55 a phone/email visit should be completed to review the SLAES.

5.2.5 Interrupting Dosing

Administration of oxytocin may be interrupted on rare occasions due to other clinical conditions that temporarily prevent nasal administration, poor compliance with administration directions, or significant adverse events or acute worsening of symptoms or functioning. The treating clinician may restart treatment at the same or a lower dose after assessment of the participant (including email/phone with participant’s caregiver). The lead site should be informed of interrupted dosing lasting more than 1 week.

Table 3: Possible Dosing Options

| DOSE NAME | A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V |
| Total Morning Dose | 8 | 8 | 16 | 16 | 24 | 32 | 16 | 24 | 24 | 32 | 40 | 24 | 32 | 40 | 48 | 32 | 40 | 32 | 40 | 40 | 48 | 40 |
| Total Afternoon Dose | 0 | 8 | 0 | 8 | 0 | 0 | 16 | 8 | 16 | 8 | 0 | 0 | 24 | 16 | 8 | 0 | 24 | 16 | 32 | 24 | 32 | 24 | 40 |
| Total Daily Dose | 8 | 16 | 16 | 24 | 24 | 32 | 32 | 32 | 40 | 40 | 40 | 48 | 48 | 48 | 48 | 48 | 48 | 56 | 56 | 64 | 64 | 72 | 72 | 80 |
5.3 Accountability Procedures for the Study Intervention/Investigational Product(s)

Subjects (or their parent/LAR) will be asked to return all previously dispensed product at the next office visit. Staff will return all unused product to the site’s investigational pharmacy for destruction. Sites should make all attempts to collect investigational product after the final phone/email contact even though subjects will not be returning to the clinic for an in person visit.

5.4 Assessment of Subject Compliance with Study Intervention/Investigational Product

Due to the difficulties of measuring compliance with weight, we will utilize a parent completed diary to measure subject compliance with medication treatment. Each daily dose morning and afternoon, will be recorded by the parent/caregiver on this diary.

5.5 Blinding/Unblinding

Due to the short half-life of oxytocin (estimated 3-15 minutes), and the lack of any treatment for overdose, unblinding will not be permitted in this study. The knowledge of treatment assignment will not alter the subject’s immediate management, so therefore unblinding is not deemed appropriate for this study. Instead, in the case of a medical emergency, unexpected serious adverse reaction or clinician judgment, the study medication may be interrupted. Study medication may be interrupted (temporarily discontinued) at the discretion of any treating physician at a site at any time without prior approval from the site PI or Steering Committee (SC). In the case when the treatment is interrupted, the subject may be re-challenged if the case is discussed and approved by the SC.

5.6 Concomitant Medications/Treatments

All concomitant medications will be recorded. PRNs will not be recorded unless: they are taken for a period of 2 weeks or more AND they are taken more than 57% of the time (ie: 9 out of 15 days) OR the clinician feels there is a compelling reason to document them. The physician will record any changes to the subjects’ psychiatric and non-psychiatric medications from baseline throughout the course of the study.
### 6.0 Schedule of Events

<table>
<thead>
<tr>
<th>Procedure</th>
<th>Scrn</th>
<th>Double Blind Treatment</th>
<th>Open Treatment</th>
<th>FU</th>
</tr>
</thead>
<tbody>
<tr>
<td>Procedure</td>
<td>W0</td>
<td>W2</td>
<td>W4</td>
<td>W8</td>
</tr>
<tr>
<td>ADOS-2</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ADI-R</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stanford Binet/Mullen</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DSM-V Checklist</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inclusion/Exclusion</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Demographics</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Family Med Hx (NIH Form)</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Randomization Form</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GSSD Acquisition Form/GUID Record</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Con Meds</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Vital Signs</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Med/Psych History (SLAES)</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adverse Effects (SLAES/Supiadiated)</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Full Physical Exam (NIH Form)</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Focused Clinical Physical Exam</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Medical History (NIH Form)</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CGI S and P</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>VAS Change (Clinician and Coord)</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Social Skills Therapies</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Psychosocial Therapies</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Laboratory</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ECG</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female Reproductive Status</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Urine/Serum Pregnancy</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Safety labs</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>mRNA sample</td>
<td>X</td>
<td>X**</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methylation sample</td>
<td>X</td>
<td>X**</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Plasma/salivary oxytocin</td>
<td>X</td>
<td>X**</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Whole blood serotonin</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Parent Questionnaires</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Questionnaire Guidance Form</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Social Opportunity Questionnaire</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>ABC</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>PDDBI-SV</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>CASI-S</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Caregiver Strain</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vineland-II (Survey Form)</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SRS-2</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Subject Completed Questionnaires</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reading Mind in Eyes Test</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Self-Rating of social function</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medication</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oxytocin Administration Instructions</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SOARS-B Parent Dose Sheet</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Risks Handout</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medication Compliance</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Oxytocin Dosing Log (staff)</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Medication Diary Dispensed</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
</tbody>
</table>

0-CGI-S only at baseline, CGI-I and CGI-S at most other time points (office visits)
1-Required at screening but can be done at any time during the course of the study at physician discretion. Must have a negative pregnancy test within two weeks of baseline.
2-Safety labs to include: glucose (random), CO2, Cl, K, Na, Creatinine, BUN, AST, ALT, full urinalysis, urine pregnancy in pubertal girls. Screening safety labs must be repeated if more than 12 months between screening and baseline.
3- Assessment will be obtained only in participants who have fluent phrase speech & can define basic feelings and friendship.
4- Completed each time the participant returns study medication
5- The appropriate SOARS-B Parent Dose Sheet should be given at each time dose changes to parents
6-Stanford Binet or Mullen may be completed at physician discretion
7- At physician discretion
*Must be given at baseline, but also can be given at any other time during the course of the study at study staff discretion
**Optional redraw of mRNA, plasma/salivary oxytocin, and methylation at baseline for those who may have had a lengthy time between screening and baseline (not safety labs)
Procedures for visits are allowed to be completed on separate days, however, subjects may not be dispensed open label medication until all week 24 procedures are completed.

### 6.1 Screening

NOTE: At any point in time, visits may be referred to as months or weeks. For the purposes of this protocol 1 month = 4 weeks (28 days).
Screening Visit (can be divided into multiple visits, if necessary) ~ approximately 6 hours
Subjects will complete the following procedures and assessments at the Screening visit:

- Provide written informed consent/assent (subject and/or parent/caregiver/LAR)
- Inclusion/Exclusion criteria checklist
- Medical/psych history completed by medical physician using SLAES and suicidality assessment
- Medical history and family medical history using the NIH-specific form
- Urine or serum pregnancy test for females of childbearing potential
- Females of childbearing potential will be asked to confirm the date of their last menstrual cycle and confirm contraception use if sexually active
- ECG (pediatric cardiologist will read/confirm)
- Review of current concomitant medication use
- Full Physical examination (using NIH form including examination of body systems, head circumference and measurement of height and weight on standard scales)
- Full vital signs (heart rate, blood pressure, and temperature)
- Safety Labs (to the extent possible, blood samples will be obtained at approximately the same time of day and under non-fasting conditions)
- Genetics (Methylation/mRNA sample)
- Plasma/salivary Oxytocin (ideally drawn between 2pm and 6pm)
- Whole blood serotonin
- ADOS-2 (must be completed prior to randomization) and ADI-R (optional at physician discretion)
- Stanford Binet (abbreviated-ABIQ) or Mullen.
  - For randomization purposes: The Mullen receptive language subscale MUST be completed on subjects who are 5 years, 8 months and younger if the Stanford Binet is completed
- DSM-5 Checklist

Subjects may return for multiple screening visits in cases where assessments could not be completed in one visit (i.e., time constraints, subject noncompliance, etc.).

The first set of Genetics and Plasma Oxytocin samples will be drawn at the Screening visit(s) in conjunction with safety labs to reduce the number of needle pricks during the study. However, the subject may choose to wait to have these samples drawn until their Baseline visits once their eligibility has been confirmed. If the samples have been collected and the subject is determined to be ineligible, the blood samples collected for these purposes will be destroyed. If there is more than 12 months between screen and baseline then safety labs will have to be re-drawn to ensure safety of the participant.

6.2 Randomized Double-Blind Treatment Phase: Oxytocin or Placebo (24 weeks; Week 0-Week 24)

Baseline Visit (Week 0) ~ approximately 3-4 hours
Subjects will complete the following procedures and assessments at the Baseline visit:
• Confirmation of Inclusion/Exclusion criteria
• Review all current medications (concomitant medication log)
• Focused Clinical Physical examination
• Full vital signs (heart rate, blood pressure, temperature)
• Females of childbearing potential will be asked to confirm the date of their last menstrual cycle and confirm contraception use if sexually active
• Females of childbearing potential must have had a negative pregnancy test (either urine or serum) within 2 weeks of baseline visit
• Demographics (age, sex, race, ethnicity, date of birth)
• SLAES (monitoring for adverse events) and suicidality assessment
• Oxytocin Dosing Log
• Social Reciprocity Scale (SRS-2)
• Vineland Adaptive Behavior (Vineland-II Survey Form)
• Caregiver Strain Questionnaire
• Aberrant Behavior Checklist
• PDDBI-SV
• CASI-5 (Sprafkin, Gadow et al. 2002; Gadow and Sprafkin 2009)
• CGI-S and baseline description of overall functioning
• Social Skills Therapy Log
• Psychosocial Therapy Log
• Questionnaire Guidance Form
• Social Opportunity Questionnaire
• Reading Mind in Eyes Test (RMET), if cognitively able
• Self-Rating of Social Functioning, if cognitively able
• Medication Diary dispensed to caregiver
• Parent Handout (study drug administration instructions)
• Parent Handout (study drug dosing guidelines)
• Parent Handout (risks)
• Randomization
• GUID Record Form
• For randomization purposes: The Mullen receptive language subscale MUST be completed on subjects who are 5 years, 8 months and younger if the Stanford Binet was completed, this must be done prior to randomization in the database
• Visual Analogue Scale of Change (Clinician), baseline description of functioning only
• OPTIONAL redraw of mRNA, plasma/salivary oxytocin, and methylation for those subjects who may have had a lengthy time between screening and baseline appointments
• Participants or their caregivers will be taught to administer the nasal spray, alternating nostrils, by the study coordinators who will demonstrate medication administration. The caregivers will be provided with suggestions for how to encourage their children to comply with the procedure including setting up a fun routine and providing rewards.
• Caregivers will also be provided with a dosing handout (Parent Dose Sheet) to describe how many sprays of which bottle to take daily.
• Medication Diary Dispensed. This monitors subjects’ weekly dosing to ensure that participants are reaching their optimal dose. The study staff will fill in the dates at each
visit, as well as the dosing (if applicable). The caregiver will also be asked to complete a medication diary to indicate when doses were administered. Subjects will be given enough oxytocin/placebo nasal spray to last them until their next visit. They will take it once or twice a day. Caregivers will be instructed to administer the first dose on the afternoon of the baseline visit, between 12PM and 4PM.

- Parents will be given a hand out which highlights all the cardiac and anaphylaxis risks. The handout will also include information about how to monitor their child’s pulse and what the normal ranges for pulse are based on age. Staff will review handout with parent to ensure that they understand all aspects of the handout.

**Week 2 Email-10 minutes**

Between week 0 and week 4 (at around week 2) staff will send the new dose schedule to the family to titrate the dose up. The families will be instructed to contact the study staff at any time if they feel that their child cannot tolerate the next dose.

**Week 4 ~ approximately 1-2 hours**

Subjects will complete the following procedures and assessments at the week 4 visit:

- Review all current medications (concomitant medication log)
- Focused Clinical Physical examination
- Full vital signs (heart rate, blood pressure, temperature, height and weight on standard scales)
- Females of childbearing potential will be asked to confirm the date of their last menstrual cycle and confirm contraception use if sexually active
- SLAES (monitoring for adverse events) and suicidality assessment
- CGI-I and CGI-S
- Visual Analogue Scale of Change (Clinician)
- Visual Analogue Scale of Change (Coordinator)
- Social Skills Therapy Log
- Psychosocial Therapy Log
- Aberrant Behavior Checklist
- PDDBI-SV
- Questionnaire Guidance Form
- Social Opportunity Questionnaire
- Oxytocin Dosing Log
- Medication Diary dispensed to caregiver. The caregivers will be provided with a dosing handout to monitor subjects’ weekly dosing to ensure that participants are reaching their optimal dose. The study staff will fill in the dates at each visit, as well as the dosing (if applicable).
- Caregivers will also be given the Parent Dose Sheet that describes how many sprays to take of the study medication.
- Caregivers will be given a supply of medication

**Week 8 ~ approximately 1-2 hours**

Subjects will complete the following procedures and assessments at the week 8 visit:

- Review all current medications (concomitant medication log)
• Focused Clinical Physical examination
• Full vital signs (heart rate, blood pressure, temperature, height and weight on standard scales)
• Females of childbearing potential will be asked to confirm the date of their last menstrual cycle and confirm contraception use if sexually active
• SLAES (monitoring for adverse events) and suicidality assessment
• CGI-I and CGI-S
• Visual Analogue Scale of Change (Clinician)
• Visual Analogue Scale of Change (Coordinator)
• Social Skills Therapy Log
• Psychosocial Therapy Log
• Aberrant Behavior Checklist
• PDDBI-SV
• Questionnaire Guidance Form
• Social Opportunity Questionnaire
• Reading Mind in Eyes Test (RMET), if cognitively able
• Genetics (Methylation/mRNA sample)
• Plasma/salivary Oxytocin (ideally drawn between 2pm and 6pm)
• Whole blood serotonin
• Oxytocin Dosing Log
• Medication Diary dispensed to caregiver (provide 2 months’ supply of diaries). The caregivers will be provided with a dosing handout to monitor subjects’ weekly dosing to ensure that participants are reaching their optimal dose. The study staff will fill in the dates at each visit, as well as the dosing (if applicable).
• Caregivers will also be given the Parent Dose Sheet that describes how many sprays to take of the study medication.
• Caregivers will be given a supply of medication (to last until week 16 visit)

**Week 12 ~ approximately 30 minutes-**
Subjects will complete the following assessments at the week 12 visit:
• Aberrant Behavior Checklist
• PDDBI-SV
• Questionnaire Guidance Form
• Social Opportunity Questionnaire
• SRS-2

**Week 16 ~ approximately 1-2 hours**
Subjects will complete the following procedures and assessments at the week 16 visit:
• Review all current medications (concomitant medication log)
• Focused Clinical Physical examination
• Full vital signs (heart rate, blood pressure, temperature, height and weight on standard scales)
• Females of childbearing potential will be asked to confirm the date of their last menstrual cycle and confirm contraception use if sexually active
• SLAES (monitoring for adverse events) and suicidality assessment
• CGI-I and CGI-S
• Visual Analogue Scale of Change (Clinician)
• Visual Analogue Scale of Change (Coordinator)
• Social Skills Therapy Log
• Psychosocial Therapy Log
• Aberrant Behavior Checklist
• PDDBI-SV
• Questionnaire Guidance Form
• Social Opportunity Questionnaire
• Oxytocin Dosing Log
• Medication Diary dispensed to caregiver. The caregivers will be provided with a dosing handout to monitor subjects’ weekly dosing to ensure that participants are reaching their optimal dose. The study staff will fill in the dates at each visit, as well as the dosing (if applicable).
• Caregivers will be given enough medication to last until the next visit.
• Caregivers will also be given the Parent Dose Sheet that describes how many sprays to take of the study medication.

**Week 20 ~ approximately 1-2 hours**
Subjects will complete the following procedures and assessments at the week 20 visit:
• Review all current medications (concomitant medication log)
• Focused Clinical Physical examination
• Full vital signs (heart rate, blood pressure, temperature, height and weight on standard scales)
• Females of childbearing potential will be asked to confirm the date of their last menstrual cycle and confirm contraception use if sexually active
• SLAES (monitoring for adverse events) and suicidality assessment
• CGI-I and CGI-S
• Visual Analogue Scale of Change (Clinician)
• Visual Analogue Scale of Change (Coordinator)
• Aberrant Behavior Checklist
• PDDBI-SV
• Social Skills Therapy Log
• Psychosocial Therapy Log
• Questionnaire Guidance Form
• Social Opportunity Questionnaire
• Oxytocin Dosing Log
• Medication Diary dispensed to caregiver. The caregivers will be provided with a dosing handout to monitor subjects’ weekly dosing to ensure that participants are reaching their optimal dose. The study staff will fill in the dates at each visit, as well as the dosing (if applicable).
• Caregivers will be given enough supply of medication to last until the next visit.
• Caregivers will also be given the Parent Dose Sheet that describes how many sprays to take of the study medication.
6.3 Open-Label Treatment Phase

**Week 24** ~approximately 3-4 hours (end of double-blind, start of Open-Label Treatment Phase)

Subjects will complete the following procedures and assessments at the week 24 visit:

- Review all current medications (concomitant medication log)
- Focused Clinical Physical examination
- Full vital signs (heart rate, blood pressure, temperature, height and weight on standard scales)
- Females of childbearing potential will be asked to confirm the date of their last menstrual cycle and confirm contraception use if sexually active
- SLAES (monitoring for adverse events) and suicidality assessment
- CGI-I and CGI-S
- Social Skills Therapy Log
- Psychosocial Therapy Log
- Aberrant Behavior Checklist
- Vineland
- CSQ
- CASI-5
- PDDBI-SV
- Questionnaire Guidance Form
- Social Opportunity Questionnaire
- Reading Mind in Eyes Test (RMET), if cognitively able
- Self-Rating of Social Functioning, if cognitively able
- SRS-2
- Genetics (Methylation/mRNA) sample
- Plasma/salivary Oxytocin (ideally drawn between 2pm and 6pm)
- ECG
- Safety Labs
- Whole blood serotonin
- Risks Handout
- ADOS-2 (optional measure at site discretion)
- Oxytocin Dosing Log
- Stanford Binet/Mullen
- Visual Analogue Scale of Change (Clinician)
- Visual Analogue Scale of Change (Coordinator)
- Caregivers will be given enough supply of medication to last until their next visit
- Caregivers will also be given the Parent Dose Sheet that describes how many sprays to take of the study medication.
- Medication Diary dispensed to caregiver The caregivers will be provided with a dosing handout to monitor subjects’ weekly dosing to ensure that participants are reaching their optimal dose. The study staff will fill in the dates at each visit, as well as the dosing (if applicable).
**Week 28 ~ approximately 1-2 hours (dose increased to target dose unless not clinically indicated)**

Subjects will complete the following procedures and assessments at the week 28 visit:

- Review all current medications (concomitant medication log)
- Focused Clinical Physical examination Full vital signs (heart rate, blood pressure, temperature, height and weight on standard scales)
- Females of childbearing potential will be asked to confirm the date of their last menstrual cycle and confirm contraception use if sexually active
- SLAES (monitoring for adverse events) and suicidality assessment
- CGI-I and CGI-S
- Visual Analogue Scale of Change (Clinician)
- Visual Analogue Scale of Change (Coordinator)
- Aberrant Behavior Checklist
- PDDBI-SV
- Social Skills Therapy Log
- Psychosocial Therapy Log
- Questionnaire Guidance Form
- Social Skills Therapy Log
- Psychosocial Therapy Log
- Social Opportunity Questionnaire
- Oxytocin Dosing Log
- Caregivers will be given enough supply of medication to last until their next office visit.
- Caregivers will also be given the Parent Dose Sheet that describes how many sprays to take of the study medication.
- Medication Diary dispensed to caregiver (provide 2 months’ supply of diaries). The caregivers will be provided with a dosing handout to monitor subjects’ weekly dosing to ensure that participants are reaching their optimal dose. The study staff will fill in the dates at each visit, as well as the dosing (if applicable).

**Week 36 ~ approximately 1-2 hours**

Subjects will complete the following procedures and assessments at the week 36 visit:

- Review all current medications (concomitant medication log)
- Focused Clinical Physical examination
- Full vital signs (heart rate, blood pressure, temperature, height and weight on standard scales)
- Females of childbearing potential will be asked to confirm the date of their last menstrual cycle and confirm contraception use if sexually active
- SLAES (monitoring for adverse events) and suicidality assessment
- CGI-I and CGI-S
- Visual Analogue Scale of Change (Clinician)
- Visual Analogue Scale of Change (Coordinator)
- Aberrant Behavior Checklist
- PDDBI-SV
- Oxytocin dosing log
- Social Skills Therapy Log
- Psychosocial Therapy Log
- Questionnaire Guidance Form
• Social Opportunity Questionnaire
• SRS-2
• Safety Labs (blood and urine)
• Methylation sample
• mRNA sample
• Plasma/salivary oxytocin (ideally drawn between 2pm and 6pm)
• Medication Diary dispensed to caregiver (provide with 3 months’ supply of diaries)
• The caregivers will be provided with a dosing handout to monitor subjects’ weekly dosing to ensure that participants are reaching their optimal dose. The study staff will fill in the dates at each visit, as well as the dosing (if applicable).
• Caregivers will be given enough supply of medication to last until their next visit.
• Caregivers will also be given the Parent Dose Sheet that describes how many sprays to take of the study medication.
• For individuals participating in the PK study, there is no need for an additional tube for the regular plasma oxytocin levels. The T0 in the PK study serves as the plasma OT levels for this visit.

**Week 48 ~ approximately 3-4 hours (End of Treatment Visit)**
Subjects will complete the following procedures and assessments at the week 48 visit:
• Review all current medications (concomitant medication log)
• Focused Clinical Physical examination
• Full vital signs (heart rate, blood pressure, temperature, height and weight on standard scales)
• Females of childbearing potential will be asked to confirm the date of their last menstrual cycle and confirm contraception use if sexually active
• SLAES (monitoring for adverse events) and suicidality assessment
• CGI-I and CGI-S
• Social Skills Therapy Log
• Psychosocial Therapy Log
• Aberrant Behavior Checklist
• Vineland
• CSQ
• CASI-5
• PDDBI-SV
• Questionnaire Guidance Form
• Social Opportunity Questionnaire
• Reading Mind in Eyes Test (RMET), if cognitively able
• Self-Rating of Social Functioning, if cognitively able
• SRS-2
• Plasma/salivary Oxytocin (ideally drawn between 2pm and 6pm)
• Safety Labs (optional at physician discretion)
• Oxytocin Dosing Log
• Visual Analogue Scale of Change (Clinician)
• Visual Analogue Scale of Change (Coordinator)

**Week 53-55- OFF treatment follow-up**

This visit is to be completed shortly after the last dose of study medication. This may be completed via phone or email.
  - SLAES (monitoring for adverse events)
  - All attempts will be made by study staff (and documented) to obtain all dispensed bottles of medication

**PK Visits (Optional)**

In order to assess the PK (pharmacokinetic) properties of oxytocin, a select group of subjects who participate in the SOARS-B trial will be asked to participate in the PK study. Study staff will select the participants based on a) their willingness to participate and b) their ability to tolerate the study procedures. A total of 18 subjects will be enrolled across all 6 sites for the week 32 samples. There will be 6 subjects in each of the following age groups: 3-6, 7-12 and 13-17 years old. Each site will be asked to enroll one subject from each of the age groups. There will be a separate consent form for this optional study.

**Target Dose PK sample (48 IU TDD)**

- This visit may occur any time after week 32 (48 IU TDD)
- This visit can be completed at any visit after week 32 or at an unscheduled visit
- There will be a target of 6 participants in each age cohort total if possible please also obtain vitals and PDDBI-SV and ABC

Procedures are as follows:
  - IV placement by study staff (saline solution only)
  - Plasma oxytocin draw at T = 0 (time 0, immediately after insertion)
  - Administration of intranasal oxytocin (target dose = 24IU but will be whatever dose the subject is currently prescribed to as part of the SOARS-B protocol)
  - Plasma oxytocin draw at T = 15 minutes
  - Plasma oxytocin draw at T = 30 minutes
  - Plasma oxytocin draw at T = 45 minutes
  - Plasma oxytocin draw at T = 60 minutes
  - If feasible plasma oxytocin draw at T= 2-7 hours post dose
  - Total blood volume = 42 mL (7mL per draw times 6 draws)
Max Open Label Dose PK sample (72 IU TDD)

- This visit may occur any time after the highest dose has been achieved (at an unscheduled visit or regularly scheduled visit)
- The target is to have 2-6 participants receiving the 72 IU total dose, (at all sites) regardless of age
- If this is not occurring at a regularly scheduled visit, please also obtain vitals and PDDBI-SV and ABC.

Procedures are as follows:
- IV placement by study staff (saline solution only)
- Plasma oxytocin draw at T = 0 (time 0, immediately after insertion)
- Administration of intranasal oxytocin (target dose = 40IU BID)
- Plasma oxytocin draw at T = 15 minutes
- Plasma oxytocin draw at T = 30 minutes
- Plasma oxytocin draw at T = 45 minutes
- Plasma oxytocin draw at T = 60 minutes
- If feasible plasma oxytocin draw at T= 2-7 hours post dose
- Total blood volume = 42 mL (7mL per draw times 6 draws)

Additional Risks for IV

Most of the risks for IV insertion are the same as for venipuncture (bruising, pain, possible infection). Complications of gaining IV may include infiltration, hematoma, an air embolism, phlebitis, and intra-arterial injection. Infiltration is caused by the infusion of fluid outside the vesicles (vein), into the surrounding soft tissue. This is generally caused by poor placement of a needle outside of the vessel lumen. Clinically, you will notice swelling of the soft tissue surrounding the IV, and the skin will feel cool, firm, and pale. IV fluids are not dangerous to the surrounding soft tissues however certain medications can be toxic. We will not be administering any medications only IV fluids therefore this will not be an issue in our study. A hematoma occurs when there is leakage of blood from the vessel into the surrounding soft tissue. This can occur when an IV catheter passes through more than one wall of a vessel or if pressure is not applied to the IV site when the catheter is removed. A hematoma can be controlled with direct pressure and will resolve over the course of 2 weeks. An air embolism occurs as a result of a large volume of air entering the patient's vein via the IV administration set. Air embolisms are rare and easily prevented by making sure that all the air bubbles are out of the IV tubing before placement. Phlebitis is inflammation of the vein which occurs due to the pH of the agent being administered during the administration of the IV, since we are not placing any medications into the IV we will not be at risk for this complication. An intra-arterial injection occurs very rarely. This can easily be prevented, by making sure that the needle is inserted in a vein. An experienced phlebotomist would not have an issue with the placement. If an artery is cannulated, there will be a pumping of bright red blood back into the angiocath, which would not be seen when you cannulate a vein. In the case of intraarterial injection, it is the intravenous drugs which pose
severe problems, rather than the IV solution and since we will not be placing any drugs into the IV this will not be an issue for our study. In order to minimize these risks, we will ensure that all study staff that place the IV are well trained in proper procedures and use aseptic procedures.

### 6.5 Early Termination Visit

If a subject terminates from the study early, then the following procedures should be completed as close as possible to the last dose. These procedures may be completed over the phone/email or in an office visit:

- SLAES
- Suicidality assessment
- CGI-I/S
- Con Meds
- Psychosocial/Social Skills Therapy Logs
- Vitals (only if in office)
- Self-Rating of Social Functioning (only if in office)
- RMET (only if in office).

The questionnaires from the week 24 visit should be sent to the families and completed as close to the last dose taken as possible. If in open-label phase send week 48 questionnaires.

Any subject who is not able to return to the clinic or available for a phone call for an early termination visit within 2 weeks of their last dose will be considered lost to follow up no ET visit is required. All efforts should be made to retrieve the medication bottles from the families either mailed back or in person.

### 6.6 Unscheduled Visit or Re-Evaluation Visit

Subjects may be asked to come in for an unscheduled visit at any time during the course of the study if the treating physician feels it is necessary to see the subject in person or to complete a PK visit. Subjects will be instructed to contact the site between scheduled visits if there are any issues that need to be addressed.

Subjects may also be re-evaluated with appropriate assessments completed for any of the following reasons:

- If the subject’s dose is mandatorily reduced, then these assessments should be completed 2-4 weeks after the dose has been reduced.
- If the subject has had a CGI-I score of 6 or 7, then the assessments should be completed two-four weeks later at physician discretion.

During these visits, all efforts should be made to obtain the following assessments:

- Vital signs (only if in person visit)
- Review of concomitant medications
- SLAES (adverse events) and suicidality assessment
- CGI-S and CGI-I
- Focused Clinical Physical Exam (only if in person visit)
• If physician feels it is indicated, safety labs or ECG may be obtained.

6.7 Unscheduled Assessments

If the site learns that a participant’s treatment has been interrupted for 1 week or longer, an unscheduled visit should be performed.

7 STUDY PROCEDURES/EVALUATIONS

7.1 Study Assessments

Parent Assessments
• Questionnaire Guidance Form: This form will give parents guidance on time frames and specific instructions for how to complete the questionnaires. This form was created by study staff with guidance from manuals from the standardized forms listed below.
• Social Opportunities Questionnaire: This created form asks parents to rate how frequently their child has the opportunity to interact with different individuals in the community, home, school and daycare/after-school setting. It also asks, of those opportunities that their child has, does their child actually utilize those opportunities to interact with individuals in a social manner.
• Social Reciprocity Scale-2: This 65-item rating scale measures the severity of autism spectrum symptoms as they occur in natural social settings (Constantino, Davis et al. 2003). Completed by a parent or teacher in just 15 to 20 minutes, the SRS provides a clear picture of a child's social impairments, assessing social awareness, social information processing, capacity for reciprocal social communication, social anxiety/avoidance, and autistic preoccupations and traits. It is appropriate for use with children from 4 to 18 years of age. The SRS measures impairment on a quantitative scale across a wide range of severity--which is consistent with recent research indicating that autism is best conceptualized as a spectrum condition rather than an all-or-nothing diagnosis. The SRS-R will take the parent/caregiver/LAR approximately 10 minutes to complete.
• Pervasive Developmental Disorders Behavior Inventory (PDDBI-Screening Version) - The PDDBI-SV examines both adaptive and maladaptive behaviors related to social behaviors in autism. It is a parent/caregiver questionnaire and has 18 items. It takes about 5-10 minutes to administer.
• Aberrant Behavior Checklist (ABC)-The ABC focuses on problem behaviors in five subdomains: irritability, attention, repetitive behaviors, unusual speech, and social withdrawal. This should take the caregiver approximately 10 minutes to complete.
• Caregiver Strain Questionnaire (CSQ – Berument): The CSQ will assess family stress and was developed for caregivers of children with developmental disabilities. This should take the caregiver approximately 5 minutes to complete.
• Medication Diary: Caregivers will be asked to record each dose given to the child on a written log. Caregivers will be asked to return this at each visit for the study team to review if there are any medication compliance issues.
• **Parent Handout (Risks):** Caregivers will be given an informational handout at baseline (beginning of Randomized Phase) and again at week 24 (beginning of Open Label Phase). This handout will describe possible symptoms to look for.

• **Dosing Guide/Medication Administration Form:** Caregivers will be given an informational handout that describes study drug administration and dosing guidelines. Participants will be instructed to increase the dose per the titration schedule as long as there are no problems and will be strongly encouraged to contact the study coordinator if there are any concerns.

• **Vineland Scales of Adaptive Functioning (2nd edition, Parent/Caregiver Rating Form):** The VABS-II is a survey administered to a parent or caregiver in a questionnaire format and is organized around four Behavior Domains: Communication, Daily Living Skills, Socialization, and Motor Skills. The VABS-II will take the parent/caregiver/LAR approximately 20-60 (average 30) minutes to complete, depending on the subject’s age and level of functioning. For the purposes of this study, we will not be assessing maladaptive behaviors.

• **Childhood Anxiety Sensitivity Index (CASI-5):** This scale is designed for measuring anxiety sensitivity (i.e., the belief that anxiety symptoms have negative consequences. There will be one form that is for children ages 3-4 and a different one for ages 5-17.

**Physician/Clinician Assessments**

• **Clinical Global Impressions Scale:** Overall psychiatric functioning will be assessed with the severity (CGI-S) and improvement (CGI-I) subscales of the CGI (Guy 1976). CGI-S items are rated from 1 (normal, not ill) to 7 (very severely ill). CGI-I items are rated from 1 (very much improved) to 7 (very much worse).

• **Physical Examination:** A physical examination can include, but is not limited to, abdominal palpation to assess for liver enlargement, assessing for decreased tone and postural problems, increased drooling and poor orofacial tone, problems holding head up as well, difficulty with coordination of motor actions. A more thorough exam will be done at screening and a more brief/clinician focused one completed at subsequent in person visit.

• **Concomitant Medication Log:** At screening, the physician will make a list of any medications the subject is currently taking (ie: on the day of screening). The physician will record any changes to the subjects’ psychiatric and non-psychiatric medications from screening throughout the course of the study. PRNs will not be recorded unless:
  - they are taken for a period of 2 weeks or more AND they are taken more than 57% of the time (ie: 9 out of 15 days)
  - the clinician feels there is a compelling reason to document them in which case this can be documented in a note to file. Example: a PRN that is used to address an AE may be noted directly on the SLAES form for clinician reference in the future, but will not be data entered.

• **Inclusion/Exclusion:** A checklist will be completed to ensure all inclusion and none of the exclusion criteria are met.

• **DSM-V Checklist for Autism:** The proposed DSM-V criteria for autism will be documented in the form of a checklist for a clinician/physician to complete.
• **Family Medical History:** This form will ask for information about genetic, mental health and medical conditions of relatives of the subject.

• **Medical History:** This form will ask about the subject’s medical history such as surgeries, medical procedures etc.

• **Oxytocin Dosing Log:** This log is completed by the physician to record all changes in dosing of oxytocin. It will include start/stop dates of when the dose changes.

**Trained Rater/Physician**

• **Systematic Longitudinal Adverse Events Scale (SLAES):** systematic elicitation and screening of adverse events will be completed using the SLAES. This will also be used at screening and baseline to obtain a comprehensive psychiatric and medical history of the patient.

• **Suicidality Assessment:** The physician will use clinical judgment to determine if the participant understands the concepts of death and making one’s self die or hurt. If the participant is deemed able to understand these concepts they will be asked if they have had any thoughts about wanting to die, wanting to hurt themselves, wanting to kill themselves and if s/he has done anything to hurt himself/herself so he/she would die or have done anything to hurt himself/herself for any other reason. If the participant is deemed not to understand these concepts, his/her caregiver will be queried by asking whether the child has said or done anything that makes the parent think the child wanted to die, to hurt himself/herself or to kill himself/herself and asking about suicidal behaviors. If any are endorsed, the caregiver will also be asked if this is a significant change in severity or frequency from the participant’s baseline. The clinician will determine whether the behaviors clearly do not appear stereotypic, might be stereotypic and are clearly stereotypic (e.g. chronic repeated head banging or self biting).

• **Female Reproductive Form:** We will record the last menstrual period, document irregular periods and verify continued use of two forms of birth control (if sexually active).

• **Vital Signs:** Vital signs will be measured at each visit and will include heart rate, sitting blood pressure, and temperature.

• **Stanford Binet (5th edition):** The Stanford-Binet intelligence scale is a standardized test that assesses intelligence and cognitive abilities in children and adults aged two to 85+ years. The Stanford-Binet Scale tests intelligence across four areas: verbal reasoning, quantitative reasoning, abstract/visual reasoning, and short-term memory. The areas are covered by 15 subtests, including vocabulary, comprehension, verbal absurdities, pattern analysis, matrices, paper folding and cutting, copying, quantitative, number series, equation building, memory for sentences, memory for digits, memory for objects, and bead memory. The abbreviated IQ (ABIQ) will be used for this study and includes non-verbal fluid reasoning and verbal knowledge subtests.

• **Mullen Early Scales of Learning (Mullen):** Is for birth to 68 months and is designed to assess five scales: Gross Motor, Visual Reception, Fine Motor, Expressive Language, and Receptive Language. We will not be using the Gross Motor subtest for this study since all our participants are over 36 months. If children younger than 5 years 9 months are assessed with the ADOS Module 1 or 2, the receptive language subscale of the Mullen must be administered to determine their functional status even if the Stanford Binet has been completed.

• **Autism Diagnostic Observation Schedule-2 (ADOS-2):** The ADOS is a semi-structured assessment used to assess and diagnose individuals suspected of having autism of varying
ages, developmental levels, and language skills (from no speech to verbally fluent). The ADOS includes four modules, each requiring just 35 to 40 minutes to administer. The individual being evaluated is given just one module, depending on his or her expressive language level and chronological age. The rater will observe social and communication behaviors during various activities in the appropriate module.

- **Autism Diagnostic Interview, Revised (ADI-R):** The ADI-R is a semi-structured, investigator-based interview for caregivers of children and adults for whom autism or pervasive developmental disorders is a possible diagnosis. The revised interview has been reorganized, shortened, modified to be appropriate for children with mental ages from about 18 months into adulthood and linked to ICD-10 and DSM-IV criteria. The detailed interview focuses on early development in social and communication and self-help skills of the child, and takes approximately 2 hours to administer.

- **Demographics:** Information such as age, race, ethnicity, family status and income will be collected.

- **Electrocardiogram:** Trained staff will collect an EKG on each subject and this will be read and confirmed by a pediatric cardiologist.

- **Reading in the Mind’s Eye Task:** This computerized task consists of a series of pictures of eyes in which the subject needs to determine which emotion the eyes are expressing.

- **Self-Rating of Social Functioning:** This staff created assessment consists of several questions that asks the participant directly to reflect on their own experience with social skills.

- **Visual Analogue Scale of Change (Clinician and Coordinator):** Both the treating clinician and study coordinator (separately) will place a vertical line across a continuous 18 cm horizontal line. No change will be reflected at the midpoint of the line, extreme worsening at the leftmost side and extremely better at the right most side. Three areas will be assessed: overall functioning similar to the CGI-I, social-communicative functioning and repetitive behaviors/restricted interests. In contrast to the CGI-I, the changes will be assessed after carefully considering the individual's functioning in each of the domains at baseline as briefly described by the clinician. The outcome measure will be the distance in cm from the left end of the line to the vertical mark.

**Other**

- **GUID Record Form:** This form will record the GUIDs that are obtained for the subject and any parent who is willing to consent to have his/her blood take for the genetic repository at NIMH

- **GUID Acquisition Form:** This form is designed to obtain all the information necessary in order to assign a GUID such as full name, date of birth, city of birth (as it is written on one’s birth certificate).

- **Randomization Form:** This form will be used by study staff to enter into the database in order to determine if a subject is high functioning or low functioning for randomization purposes.

- **Social Skills Therapies Log:** This form will record the number of hours in the previous month that the child received social skills therapy.

- **Psychosocial Therapy Log:** This form will record the number of hours in the previous month that the subject received any additional psychosocial therapy such as ABA, equine therapy, speech therapy etc.
7.2 Laboratory Evaluations

7.2.1 Clinical Laboratory Evaluations

- **Chemistry Panel:** The chemistry panel will include glucose (random, non-fasting), CO2, Cl, K, Na, Creatinine, BUN, AST, ALT at Screening, week 24, and week 24. Total blood to be collected is 8.5mL in SST tube.

- **Pregnancy test:** Will be serum or urine completed at screening but can be done at any time throughout the course of the study at the physician’s discretion. Additionally, for females of childbearing potential, they must have had a negative pregnancy test (urine or serum) within 2 weeks of randomization. This can be done by an onsite urine dipstick pregnancy test either at screening or baseline (prior to randomization). This will not require any additional blood and will be collected as part of the above chemistry panel.

- **Plasma Oxytocin:** We will assay plasma oxytocin levels using standard radioimmuno assays in Dr. Pedersen’s lab in order to describe potential relationships between baseline levels and treatment response. We expect there to be minimal changes in plasma levels with intranasal administration, since oxytocin is rapidly degraded. Total 7ml of blood drawn (one 7ml lavender top tube).

- **Serotonin Levels:** Serum serotonin levels will be measured by aliquoting 200uL of whole blood from the methylation tube. No extra blood is needed for this.

- **Urinalysis:** A full urinalysis panel is required including at least the following: specific gravity, pH, color/appearance, protein, glucose, leukocyte esterase, occult blood.

- **Salivary Oxytocin:** Saliva will be collected from subjects. Subjects will be asked to hold a children’s salivary swab in their mouths under the tongue (like a thermometer) for 1.5 min.

7.2.2 Duke Genetics

**Genetics Study:** Dr. Gregory will perform the methylation and mRNA expression studies. For the methylation studies, DNA will be extracted from peripheral blood, bisulfite converted, PCR performed using primers targeted to the bisulfite-converted regions of the CpG islands in the promoter region and third intron of the **OXTR** gene, and the resulting clones sequenced to calculate percentage of methylation at each of the CpG sites. Total RNA will be extracted from blood samples, RNA quality checked and quantitative PCR run after reverse transcription using primers for **OTXR** exon 2 and the **OXT**. We will use already collected samples (after running initial analysis of mRNA expression and methylation) for unspecified genetic analysis and also for other analyses to identify possible unspecified genetic factors that may influence response to oxytocin treatment.

- Total 8.5ml of blood drawn (one 2.5ml PAX gene tube and two 3ml lavender top tubes)

8 ASSESSMENTS OF SAFETY

8.1 Adverse Events

ICH E6 defines an AE as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product regardless of its causal relationship to the study
treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding that is not directly obtained for purposes of the study), symptom, or disease temporally associated with the use of medicinal (investigational) product. The occurrence of an AE may come to the attention of study personnel during study visits and interviews of a study subject presenting for medical care, or upon review by a study monitor. All AEs will be captured on the appropriate source documentation, the Systematic Longitudinal Adverse Event Scale (SLAES). Information to be collected includes event description and clinician’s assessment of severity.

8.1.1 Treatment Emergent Adverse Events

In this trial we are documenting all AE’s, but analysis will focus only on Treatment Emergent AE’s (TEAE’s). Medical and behavioral conditions that are present at screening and/or baseline will only be considered treatment emergent adverse events if their severity increases significantly after the participant has taken at least one dose of study treatment. Intermittent conditions such as seasonal allergies will only be considered TEAEs, if the severity or frequency is significantly greater than in the previous two years. Only TEAEs will be considered in the adverse event safety analyses.

If a TEAE occurs, its relationship to study product (assessed only by those with the training and authority to make a diagnosis, which would include MD, DDS, DMD, PA, Nurse, Nurse Practitioner or DO), and resolution/stabilization will be coded at the resolution of the event or end of the subject’s participation in the study. All TEAEs occurring while on study must be documented appropriately regardless of relationship. All TEAEs will be followed to adequate resolution. If a TEAE is a severe adverse event rating (3) and an Unexpected Problem (UP-no prior history of issue/not commonly seen in autistic patients and not described as a risk of the treatment), the UP form must be completed. If a TEAE is an SAE the the SAE form and SLAES (unscheduled visit) must be completed.

Severity of Event: All AEs will be assessed by the clinician using a protocol defined grading system. For events not included in the protocol defined grading system, the following guidelines will be used to quantify intensity.

- **Mild:** events require minimal or no treatment and do not interfere with the subject’s daily activities.
- **Moderate:** events result in a low level of inconvenience or concern with the therapeutic measures. Moderate events may cause some interference with functioning.
- **Severe:** events interrupt a subject’s usual daily activity and may require systemic drug therapy or other treatment. Severe events are usually incapacitating.
- **Life-threatening:** Substantial risk dying or requires intervention to prevent death
- **Death related to AE:** Subject died as a result of the event, self-explanatory

Changes in the severity of an AE will be documented to allow an assessment of the duration of the event at each level of intensity to be performed. Adverse events characterized as intermittent require documentation of onset and duration of each episode.
**Relationship to Study Treatment:** The clinician’s assessment of an AE's relationship to test article (study drug) is part of the documentation process, but it is not a factor in determining what is or is not reported in the study. If there is any doubt as to whether a clinical observation is an AE, the event will be reported. All AEs must have their relationship to study product assessed using the terms: associated or not associated. In a clinical trial, the study product must always be suspect. To help assess, the following guidelines are used.

- **Yes (certain):** The adverse event and administration of the study drug are related in time, and a direct association can be demonstrated.
- **Likely (probably):** The adverse event and administration of the study drug are reasonably related in time, and the adverse event is more likely explained by the study drug than other causes.
- **Possible:** The adverse event and administration of the study drug are reasonably related in time, and the adverse event can be explained equally well by causes other than study drug.
- **No (unrelated):** The adverse event is clearly explained by another cause not related to the study drug.

**Pattern Definition:** This is to help the clinician define the pattern of the AE and give some clarity to timing of an event.

- **ISOLATED-** Occurs a single time
- **INTERMITTENT-** An AE that stops and starts with clear defined points (eg. seasonal allergy)
- **CONTINUOUS-** Ongoing AE (eg. migraines)

**Change/Outcome-** This should be captured in order to help the clinician make a clear decision on a severity rating and better follow the AE through time.

- No change from last AE report
- Worsening from the last AE report
- Improving from the last AE report
- Recovered from the last AE report

**Action Take-** The action taken after the report of an AE can be captured by the definitions below:

- O = None
- M = Monitoring
- CM = Conmed/Rx
- D = Decrease study med
- UP = Increase study med
- S = Interrupt study med
- W = Withdrawal from study

**8.1.2 Suicidality Assessment**
Suicidality assessments will be completed for each participant at each visit except weeks 2 and 26. The physician will use clinical judgment to determine if the participant understands the concepts of death and making one’s self die or hurt. If the participant is deemed able to understand these concepts they will be asked if they have had any thoughts about wanting to die, wanting to hurt themselves, wanting to kill themselves and if s/he has done anything to hurt himself/herself so he/she would die or have done anything to hurt himself/herself for any other reason. If the participant is deemed not to understand these concepts, his/her caregiver will be queried with the thought questions replied by saying or doing anything that makes the parent think the child wanted to die, to hurt himself/herself or to kill himself/herself and asking about suicidal behaviors.

The caregiver will also be asked if this is a significant change in severity or frequency from the participant’s baseline.

The clinician will discuss any self-injurious behaviors with the steering committee describing the events, the participant’s prior history if any of similar behaviors or suicidal ideation, and the caregiver’s perception of any change in severity or frequency of the behaviors. The steering committee will then determine whether the behaviors clearly do not appear stereotypic, might be stereotypic and are clearly stereotypic (e.g. chronic repeated head banging or self biting). These cases will also be reviewed by the medical monitor and DSMB.

8.2 Reportable Events

8.2.1 Serious Adverse Event (SAE):

An SAE is defined as an AE that meets one of the following conditions:
- Death during the period of protocol-defined surveillance
- Life-threatening event (defined as a subject at immediate risk of death at the time of the event)
- An event requiring inpatient hospitalization or prolongation of existing hospitalization during the period of protocol defined surveillance
- Results in congenital anomaly or birth defect
- Results in a persistent or significant disability/incapacity
- Any other important medical event that may not result in death, be life threatening, or require hospitalization, may be considered a serious adverse experience when, based upon appropriate medical judgment, requires medical or surgical intervention to prevent one of the outcomes listed above. Examples of such medical events include allergic bronchospasm requiring intensive treatment in an emergency room, blood dyscrasias or new onset of convulsions that do not result in inpatient hospitalization.

All SAEs will be:
- recorded on the appropriate SAE CRF
- followed through resolution by a study clinician
- reviewed and evaluated by a study clinician.

8.2.2 Unanticipated Problems (UP)

We will consider unanticipated problems involving risks to subjects or others to include, in general, any incident, experience, or outcome that meets all of the following criteria:
• unexpected (in terms of nature, severity, or frequency) given (a) the research procedures that are described in the protocol-related documents, such as the IRB-approved research protocol and informed consent document; and (b) the characteristics of the subject population being studied;
• related or possibly related to participation in the research (in the guidance document, possibly related means there is a reasonable possibility that the incident, experience, or outcome may have been caused by the procedures involved in the research); and
• suggests that the research places subjects or others at a greater risk of harm (including physical, psychological, economic, or social harm) than was previously known or recognized.

8.2.3 Pregnancy

In the case of a pregnancy of either the subject (female) or the subject’s partner (for male subjects), sites/investigators should follow the pregnancy until completing (either termination or birth). The baby should also be followed until he/she is 1 month old to assess and record any medical complications. All this information should be sent to the Coordinating Center via the above referenced contact information. The initial report (on the appropriate source document) should be to the coordinating center within 7 days of the site’s awareness.

8.2.4 Serious Suicidal Ideation

In the case of serious intentional self-harm/serious suicidal ideation, the physician/clinician should take necessary steps to ensure the safety of the subject including involuntary hospitalization (if needed). This should be reported (on the appropriate source document) to the coordinating center within 7 days of the site’s awareness.

8.2.5 Alert Lab/ECG values

Alert values for laboratory tests (clinical/safety labs) and for ECGs will be determined by the site’s treating physician and/or PI for each individual study subject. For the DSMB reports, the PIs will decide on specific values for each of the clinical labs and ECGs. In the event that a site has a lab/ECG value that is considered to alarming by either the site treating physician or site PI, this must be reported (on the appropriate source document) to the coordinating center with 7 days of the site’s awareness.

8.3 Reporting Procedures

8.3.1 Treatment Sites Reporting to Duke

Any event that is considered reportable based on section 8.2 by the PI or Subinvestigator or which meets the aforementioned criteria must be submitted to the Coordinating Center. It should be reported on the following numbers. It is preferable to have a written report (fax or email) for documentation purposes.

Coordinating Center E-mail: cheryl.alderman@duke.edu and linmarie.sikich@duke.edu
The study clinician will complete and submit the appropriate reporting form within the following timelines:

- SAEs that are deaths and immediately life-threatening events, whether related or unrelated, will be recorded on the Serious Adverse Event Form and sent by fax within 2 business days of site awareness.
- SAEs other than death and immediately life-threatening events, regardless of relationship, will be reported by fax within 7 business days of site awareness.
- UPs Form within 7 business days of the site’s awareness of the event.
- Pregnancies within 7 business days of the site’s awareness.
- Serious Suicidal Ideation within 7 business days of the site’s awareness.
- Alert lab or ECG values within 7 business days of the site’s awareness.
- Decisions to reduce dose within 7 business days.
- Interrupted dosing lasting more than 7 days within 7 business days of site’s awareness.
- Requests to delay mandatory reductions in dose within 5 business days.
- Participants with a CGI-I of 6 or 7 within 7 business days of the assessment.

Other supporting documentation of the event may be requested and should be provided as soon as possible. Sites should report SAEs, UPs and other reportable events to their local IRB’s per the local IRB’s guidelines and procedures. This may differ between sites.

8.3.2 Duke Reporting to Other Regulatory Bodies

- **Medical Monitor:** Duke will report all SAEs, UPs and other reportable events (section 8.2) to the medical monitor within 14 days and receive acknowledgment that she has reviewed them.
- **DSMB:** Duke will report SAEs, UPs and other reportable events (section 8.2) that are considered possibly related to study treatment to the DSMB within 14 days of being made aware of their occurrence.
- **FDA:**
  - To be reportable to the FDA, the event must meet 3 criteria. The investigator or the holder of the IND may make the determination if the event meets all three of the following criteria.
    - Suspected Adverse Reaction: meaning there is a reasonable probability that the drug caused the event. Meaning there is evidence to suggest a causal relationship between the drug and the adverse event.
    - Serious (use definition of serious in section 8.2.1)
    - Unexpected (use definition of unanticipated in section 8.2.2)
  - Timelines for reporting to the FDA:
    - Unanticipated fatal or life threatening adverse events (7 days)
    - Unanticipated non-fatal/non-life threatening (14 days)
- **Steering Committee:** Duke will report all SAEs/UPs/other reportable events (section 8.2) to the steering committee within 14 business days of Duke’s awareness.
• Duke’s local IRB: The coordinating center is responsible for reporting unanticipated problems to their local IRB as their local IRB has direct oversight of Duke and indirect oversight of other site’s
  o Unanticipated Problems that are serious adverse events should be reported to the IRB within one (1) week of the investigator becoming aware of the event.
  o Any other Unanticipated Problem should be reported to the IRB within two (2) weeks of the investigator becoming aware of the problem.
  o Other reportable events (section 8.2): during annual renewal

8.5 Individual Stopping Procedures

If a subject is worsening clinically (they have CGI-I score of 6-much worse or 7-very much worse on CGI-I, there has to be a return visit/phone call within 1-2 weeks to revisit/re-evaluate with CGI-I. If the subject still has 6 or 7, then case must be discussed with SC and Medical Monitor within 10 business days to get approval for the subject to continue in the trial.

Subjects may be withdrawn for any of the following reasons:
  • if clinically significant and/or personally intolerable moderate or severe adverse events occur that cannot be addressed by dose adjustment or addition of concomitant medications (these can be discussed with SC and Medical Monitor. Investigators are encouraged to try dose reduction or addition of concomitant medications prior to withdrawal of participants).
  • If a subject is worsening clinically (they have 6 much worse or 7 very much worse on CGI-I, there has to be a return visit/phone call within 1-2 weeks to revisit/re-evaluate with CGI-I. If the subject still has 6 or 7, then case must be discussed with SC and Medical Monitor to get approval for participation to continue.
  • study noncompliance
  • study physician discretion

Subjects must be withdrawn for the following reasons:
  • at the participant or guardian request
  • If the medical monitor feels worsening of their clinical condition or life threatening adverse events are likely to be related to the study treatment or procedures.

8.6 Safety Oversight

8.6.1 Independent Medical Monitor

Evdokia Anagnostou, MD has a wealth of experience in pediatric oxytocin administration as she has conducted many of her own trials. She will serve as the independent medical monitor for this study. She will review alarm values of labs and ECGs as defined by site treating physician and/or site PI, UPs, SAEs, pregnancies and serious suicidal ideation.and serious adverse events within 14 working days of their reporting and who will review all new treatment emergent adverse effects of moderate or greater severity two times a year prior to DSMB meetings. She will be available to DSMB and to steering committee to discuss concerns about safety related to the 2 above activities. She will also discuss any case in which an individual participant has significant
8.6.2 Data Safety Monitoring Board (DSMB)

The UNC TRACS Data and Safety Monitoring Board (DSMB) will monitor data from all sites. The principle role of the DSMB is to monitor the data from clinical trials to protect the safety of the research participants. To achieve this, the DSMB will: a) establish a 2 times/year schedule; b) review proposed protocols for safety and validity; c) evaluate recruitment and rate of enrollment in relation to the projected activity; d) monitor the occurrence of adverse events, serious adverse events, and early withdrawals or terminations throughout the course of the study; e) review with a designated research staff member the pattern of the study data; and f) evaluate study outcomes, when available. It will be reviewed by the DSMB 2 times/year.

8.6.3 Overall Study Stopping Criteria

At 26 week intervals, the study biostatistician will test whether there are significant differences between those on active treatment and those on placebo for Severe and Life Threatening/Fatal adverse events. The statistical analysis method will be a Fisher Exact Test. The significance level considered significant for these tests will be 0.05 without correction for multiple comparisons. If there are any significant differences that indicate greater risk for active treatment, further enrollment will be stopped, but participants currently being treated will continue. These results will be provided to the DSMB along with the summary report of enrollment and other safety data at their next regularly scheduled meeting. If the DSMB will evaluate the apparently increased risk and work with the SOARS Steering committee as necessary to develop a mutually acceptable plan for addressing the apparently increased risk. Such decisions might involve closing the study entirely, changing dosing or implementing additional monitoring.

8.6.4 Cardiac Monitoring Plan

Based on the patient’s age, gender, and height percentile, we have adapted blood pressure parameters where blood pressures above or below the set threshold will prompt the PI to consider doing an EKG. These parameters were derived from the National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents(Falkner, Daniels et al. 2004). We have likewise adapted parameters from Pediatric cardiology for practitioners(Park 2008) and Normal ECG standards for infants and children (Davignon, Rautaharju et al. 1979)to establish heart rate guidelines where patients whose heart rate is above or below these thresholds will be considered for an EKG at every visit. Finally, we will incorporate clinical signs and symptoms of cardiac risk into our assessment with the vital sign measurement and specifically query for the presence of syncope, dizziness, palpitations, shortness of breath, and bradycardia or tachycardia. The clinical parameters will be incorporated into the SLAES. The specific parameters for heart rate, blood pressure are located in Appendix A. We believe, given the low cardiac risk of oxytocin, that careful monitoring of vital signs and clinical signs and symptoms at every visit will be adequate to ensure the safety of our patients.

9 CLINICAL MONITORING
9.1 Site Monitoring Plan

Site monitoring will be conducted to ensure that the human subject protection, study procedures, laboratory, study intervention administration, and data collection processes are of high quality and meet the sponsor, ICH E6 and, when appropriate, regulatory guidelines. This section will give a general description of how site monitoring will be conducted. The data monitor will be housed at the Data Center at UNC Chapel Hill. The Data/Regulatory Monitor will monitor the database, with the data manager, in order to assess quality assurance and control issues, and will generate queries from the database. This individual will also monitor each site’s regulatory documents for completeness and accuracy (delegation of duties logs, 1572s, FDFs, general correspondence, IRB correspondence, laboratory values etc). He/she will travel to each site in order to monitor the study coordinators and the case report forms to ensure that data are collected completely and accurately. Specifics of site monitoring will be included in the separate data monitoring plan. He/she will ensure that queries are resolved. He/she will also ensure that data is properly and accurately entered into the database.

10 STATISTICAL CONSIDERATIONS

The overall statistician or his/her designee will conduct and have ultimate responsibility for all data analysis described below. All statistical computing will be done using the most recent version of SAS. The lead statistician will do the programming and perform the analyses. The analyses described below will be performed on the intent-to-treat population. Additional exploratory analyses may be performed on the per protocol population or key subsets of the sample (e.g. those participants without fluent phrase speech). All data will be explored using descriptive statistics and graphical techniques prior to any hypothesis testing. For categorical variables, we will examine frequency distributions and where appropriate contingency tables and histograms. For continuous variables, we will examine frequency distributions and, where appropriate, box-and-whisker plots. When appropriate, we will consider transformation. If necessary due to distributional considerations, we will cautiously consider a change of analysis method to a less parametric one.

10.1 Statistical Analysis (Please also see SAP)

General Modeling: Unless otherwise specified, we will fit a mixed longitudinal model with change from baseline to each post-baseline month (4 weeks) for a response variable, functioning (low versus high) as the stratification variable, center as a blocking factor, treatment (oxytocin versus placebo) as the between-subjects factor, week as a within-subjects factor, their interaction, and baseline as a covariate. The primary model used will be a mixed model with repeated measures (MMRM), treating week categorically and using an autoregressive (with a lag of 1) covariance structure. As a secondary sensitivity analysis, we will fit a random coefficients model treating week continuously with random coefficients for the intercept, slope, and slope squared, with an unstructured structure among the random coefficients. The primary hypothesis test of interest will be a test of treatment effect at week 24. Distributional assumptions will be examined using residuals. These mixed models could fail to converge or encounter difficulties based on their use of asymptotics. If they do, we will attempt to simplify the models
in order to eliminate the problems, and if necessary, move to analyses that assume compound symmetry, but use a Huynh-Feldt correction if compound symmetry fails.

**Missing Data:** The mixed models used to evaluate the continuous response variables are able to handle moderate amounts of missing data provided they are missing at random. We will examine the missing at random assumption by assessing baseline differences between dropouts and completers, as well as differences in response variables up to the point of premature withdrawal. If the missing at random assumption does not appear to be tenable, we will report the mixed models results but spend additional effort characterizing treatment effect at time of premature withdrawal or the effect of not including participants with significant missing data in supplementary analyses.

### 10.2 Sample Size Considerations

We will use a mixed longitudinal model for our primary analyses (see Statistical Analyses below). Since some aspects of the model such as covariance structure are unknown, we performed power and sample size calculations using a more conservative, simplified model corresponding to a two-group t-test on change scores. We plan to analyze two co-primary outcome measures: the ABC-SW, which will provide consistency with pivotal trials of other medications hypothesized to improve ASD social symptoms, and the combined social score, which integrates ABC-SW symptoms with the new Pervasive Developmental Disorders Behavior Inventory-Screening Version SOCDEF raw score (PDDBI-SV, Cohen 2011, also see Outcome Measures) in order to fully capture the range of impairments in reciprocal social behaviors observed in ASD. We will use an alpha of 0.025 to correct for two co-primary outcomes. SOARS-B is powered for Aim 1b to allow independent evaluation of oxytocin efficacy in low and high-functioning youth.

Standard deviations of change scores for the ABC-SW range from ~5 to 9 in several large ASD intervention trials (McCracken, McGough et al. 2002; Shea, Turgay et al. 2004; Aman, McDougle et al. 2009; King, Hollander et al. 2009; Marcus, Owen et al. 2009; Owen, Sikich et al. 2009). We consider a between groups difference of 5-7 points in ABC-SW change scores to be clinically meaningful. In our power calculations, we use conservative estimates of 9 points for the SD of ABC-SW change and 5 points for between group differences in ABC-SW changes (differential improvement on ~1/3 of items). To achieve 80% power with an alpha of 0.025 on the ABC-SW, we will require 71 participants in each treatment group within the two strata. Thus, our total required sample for the ABC-SW in Aim 1b is 284. We examined change in the combined social score in 30 3-17 year olds with ASD, 20 treated with aripiprazole and 10 medication-free controls. The mean baseline value was 33.5 (17.2 SD) and the change overall was -10.7 (SD 13.0), with a SD of change in each group of 11.9. Within each treatment group, changes in the combined social score paralleled those in the ABC-SW and PDDBI-SV, but had less variability (Sikich, personal data). We consider a between groups difference in the combined social measure changes of 10-12 to be clinically meaningful. Conservative estimates using a SD of 15 and a between groups difference of 10 in the combined social score changes results in a larger effect size for the combined social measure than for the ABC-SW. Consequently, we should have at least 80% power. A sample size of 300 will allow for 5% attrition between randomization and the first post-randomization visit. On 3/28/2016 we reduced
the attrition rate to 1% based on attrition rate observed to date which gives a final sample size of 290. Aims 1a, 3 and 4 consider all participants, resulting in much greater power than for Aim 1b. The power of moderator analyses depends on the distribution of participant characteristics and variability in methylation and mRNA expression observed, which can’t be estimated reliably at this time.

11 SUBJECT CONFIDENTIALITY

In order to protect confidentiality, only randomly assigned ID numbers rather than names will appear on clinically sensitive charts, files, and digital data. The key linking the numeric identifier and participant’s identity will be maintained on a separate drive that is double password protected and to which only the site PI and coordinator have access. Contact information will be recorded separately in double password protected files with restricted access as above. The code linking the names with the ID numbers will be securely protected with limited access. Medical records will be kept confidential with access granted only to those medical and research professionals directly involved with the study. If any scientific paper based on the data collected for this study is published, no information that could be linked to any single participant will be reported. Confidentiality will be protected to the fullest extent permitted by law. All research personnel have completed HIPPA training for researchers and human ethics training.

The samples for the methylation portion of the study (which will be sent to Simon Gregory’s team at Duke) will be single-coded, that is, labeled with a single specific code that does not carry any personal identifiers. Single coding is the current standard used in clinical research and offers additional safeguards to the subject’s identifiers compared to the HIPAA authorization. With this method it is possible to trace the samples back to a given subject with the use of the single coding key. The clinical study investigator is responsible for maintaining the coding key. This coding key will be stored separately from the research data. When stored electronically, it will be password protected as it will contain identifying information. The samples will also note the date of collection and visit number.
## APPENDIX A (Clinical Parameters for Cardiac Monitoring)

### BLOOD PRESSURE PARAMETERS FOR GIRLS

<table>
<thead>
<tr>
<th>AGE</th>
<th>MIN (5th % height)</th>
<th>MIN (95th % height)</th>
<th>MAX (5th % height)</th>
<th>MAX (95th % height)</th>
</tr>
</thead>
<tbody>
<tr>
<td>3</td>
<td>86/47</td>
<td>93/51</td>
<td>104/65</td>
<td>110/69</td>
</tr>
<tr>
<td>4</td>
<td>88/50</td>
<td>94/54</td>
<td>105/68</td>
<td>112/72</td>
</tr>
<tr>
<td>5</td>
<td>89/52</td>
<td>96/56</td>
<td>107/70</td>
<td>113/74</td>
</tr>
<tr>
<td>6</td>
<td>91/54</td>
<td>98/58</td>
<td>108/72</td>
<td>115/76</td>
</tr>
<tr>
<td>7</td>
<td>93/55</td>
<td>99/59</td>
<td>110/73</td>
<td>116/77</td>
</tr>
<tr>
<td>8</td>
<td>95/57</td>
<td>101/60</td>
<td>112/75</td>
<td>118/78</td>
</tr>
<tr>
<td>9</td>
<td>96/58</td>
<td>103/61</td>
<td>114/76</td>
<td>120/79</td>
</tr>
<tr>
<td>10</td>
<td>98/59</td>
<td>105/62</td>
<td>116/77</td>
<td>122/80</td>
</tr>
<tr>
<td>11</td>
<td>100/60</td>
<td>107/63</td>
<td>118/78</td>
<td>124/81</td>
</tr>
<tr>
<td>12</td>
<td>102/61</td>
<td>109/64</td>
<td>119/79</td>
<td>126/82</td>
</tr>
<tr>
<td>13</td>
<td>104/62</td>
<td>110/65</td>
<td>121/80</td>
<td>128/83</td>
</tr>
<tr>
<td>14</td>
<td>106/63</td>
<td>112/66</td>
<td>123/81</td>
<td>129/84</td>
</tr>
<tr>
<td>15</td>
<td>107/64</td>
<td>113/67</td>
<td>124/82</td>
<td>131/85</td>
</tr>
<tr>
<td>16</td>
<td>108/64</td>
<td>114/68</td>
<td>125/82</td>
<td>132/86</td>
</tr>
<tr>
<td>17</td>
<td>108/64</td>
<td>115/68</td>
<td>125/82</td>
<td>132/86</td>
</tr>
</tbody>
</table>
**BLOOD PRESSURE PARAMETERS FOR BOYS**

<table>
<thead>
<tr>
<th>AGE</th>
<th>MIN (5th % height)</th>
<th>MIN (95th % height)</th>
<th>MAX (5th % height)</th>
<th>MAX (95th % height)</th>
</tr>
</thead>
<tbody>
<tr>
<td>3</td>
<td>86/44</td>
<td>95/48</td>
<td>104/63</td>
<td>113/67</td>
</tr>
<tr>
<td>4</td>
<td>88/47</td>
<td>97/52</td>
<td>106/66</td>
<td>115/71</td>
</tr>
<tr>
<td>5</td>
<td>90/50</td>
<td>98/55</td>
<td>108/69</td>
<td>116/74</td>
</tr>
<tr>
<td>6</td>
<td>91/53</td>
<td>100/57</td>
<td>109/72</td>
<td>117/76</td>
</tr>
<tr>
<td>7</td>
<td>92/55</td>
<td>101/59</td>
<td>110/74</td>
<td>119/78</td>
</tr>
<tr>
<td>8</td>
<td>94/56</td>
<td>102/61</td>
<td>111/75</td>
<td>120/80</td>
</tr>
<tr>
<td>9</td>
<td>95/57</td>
<td>104/62</td>
<td>113/76</td>
<td>121/81</td>
</tr>
<tr>
<td>10</td>
<td>97/58</td>
<td>106/63</td>
<td>115/77</td>
<td>123/82</td>
</tr>
<tr>
<td>11</td>
<td>99/59</td>
<td>107/63</td>
<td>117/78</td>
<td>125/82</td>
</tr>
<tr>
<td>12</td>
<td>101/59</td>
<td>110/64</td>
<td>119/78</td>
<td>127/83</td>
</tr>
<tr>
<td>13</td>
<td>104/60</td>
<td>112/64</td>
<td>121/79</td>
<td>130/83</td>
</tr>
<tr>
<td>14</td>
<td>106/60</td>
<td>115/65</td>
<td>124/80</td>
<td>132/84</td>
</tr>
<tr>
<td>15</td>
<td>109/61</td>
<td>117/66</td>
<td>126/81</td>
<td>135/85</td>
</tr>
<tr>
<td>16</td>
<td>111/63</td>
<td>120/67</td>
<td>129/82</td>
<td>137/87</td>
</tr>
<tr>
<td>17</td>
<td>114/65</td>
<td>122/70</td>
<td>131/84</td>
<td>140/89</td>
</tr>
</tbody>
</table>

Adapted from National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents: The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents (Falkner, Daniels et al. 2004).

**HEART RATE PARAMETERS**

<table>
<thead>
<tr>
<th>AGE</th>
<th>MIN</th>
<th>MAX</th>
</tr>
</thead>
<tbody>
<tr>
<td>1-3</td>
<td>90</td>
<td>150</td>
</tr>
<tr>
<td>4-5</td>
<td>65</td>
<td>135</td>
</tr>
<tr>
<td>6-8</td>
<td>60</td>
<td>130</td>
</tr>
<tr>
<td>9-11</td>
<td>60</td>
<td>110</td>
</tr>
<tr>
<td>12-16</td>
<td>60</td>
<td>110</td>
</tr>
<tr>
<td>&gt;16</td>
<td>60</td>
<td>100</td>
</tr>
</tbody>
</table>

Adapted from Pediatric cardiology for practitioners (Park 2008) and Normal ECG standards for infants and children (Davignon, Rautaharju et al. 1979).

**14 SUMMARY OF PROTOCOL CHANGES**

Summary of Changes (Protocol version date 08 March 2013):
- Removal of whole blood serotonin collection at Months 8, 12, and 18
- Addition of salivary oxytocin collection at same time points as plasma oxytocin collection (Screening, Month 2, Month 6, Month 8, Month 12 and Month 18) (added to schedule of events and in visit descriptions)
- Addition of intelligence tests (Stanford-Binet 5/Mullen at Months 6, 12, 18 (added to Schedule of Events and in visit descriptions)
• Clarified scoring procedures on the Mullen assessment regarding when to calculate mental age for participants
• Revised Oxytocin Flexible Dosing Strategy (Table 3)
• Updated/clarified definitions and recording requirements for concomitant medications. Made clarifications regarding the documentation of PRNs
• Added specific list of prohibited meds (ones that affect brain serotonin levels)
• Added an additional reportable event section:
  o serious intentional self-harm/serious suicidal ideation
  o Pregnancy of subject or a subject’s sexual partner
• Revised language regarding study stopping criteria:
  o Added language regarding Overall Study Stopping Criteria per DSMB request
  o Changed “if moderate or severe adverse events occur that cannot be addressed by dose adjustment or addition of concomitant medications” to “if moderate or severe adverse events occur that cannot be addressed by dose adjustment or addition of concomitant medications (these can be discussed with SC and Medical Monitor. Investigators are encouraged to try dose reduction or addition of concomitant medications).”
  o Changed “clinical worsening (much worse or very much worse on CGI-I) at two consecutive visits unless explicitly discussed and agreed with SC and Medical Monitor that participant can continue in the study” to “If a subject is worsening clinically (they have score of 6 – much worse or 7 – very much worse on CGI-I, there has to be a return visit/phone call within 1-2 weeks to re-visit/re-evaluate with CGI-I. If the subject still has 6 or 7, then case must be discussed with SC and Medical Monitor to get approval for participation to continue.”
  o Changed reporting rule requirements for UPs, SAEs and other reportable events
  o Specified UNC’s responsibilities for reporting to specific authorities
  o Specified reporting requirements for other site
  o Added 2 new categories for severity of an adverse event (to be consistent with NC TraCS DSMB
    o Life-threatening: Substantial risk dying or requires intervention to prevent death
    o Death related to AE: Subject died as a result of the event, self-explanatory
• Made DSMB section consistent:
  o DSMB will meet and review the study 3x/year instead of quarterly as previously indicated
• Clarified definition of Serious Adverse Event
• Updated Tables 1 & 2 regarding Adverse Events
• Updated section regarding randomization method:
  o We will randomize centrally, using our data management system. We currently do just that in our multicenter IMPACT trial. When a site needs to randomize a subject, after baseline is assessed, the coordinator opens the Randomization form. This form uses already assessed strata to randomize from the appropriate stratum. We will not stratify by site. We felt that both functional status and age group were more likely to be related to the outcome than site, and there are limits to how many strata we can have. We will stratify by functional status (high or low) and age group (3 age groups), producing 6 strata. Dr. Hamer will generate a randomization plan for each of the 6 strata, using a permuted block algorithm with
randomly selected block sizes of 2 and 4, using SAS. The table will be exported to an Excel file and sent to the data manager, Ms. Scheer. This can be done without having Dr. Hamer ever actually see the randomization plan. (He will debug the program and when debugged, run it with a new seed for the random number generator without seeing the results.) Ms. Scheer will import the randomization plan as a table in Access. The Randomization form will use Visual Basic code and the values of the strata variables to enter the correct subset of the table and choose the first unused treatment. It will generate an ID number and send an email to the appropriate pharmacy, where drug will be assigned.

Summary of Changes (Protocol version date 21 March 2013 3.0):
- Changed dearth of safety information to limited safety information given new data emerging, Added clarifying text to the evidence for safety of sustained intranasal oxytocin treatment in ASD.
- Introduced nomenclature of “sociability factor (SF)” to replace prior references to combined social score. There is no change in how it is derived.
- Clarified the key secondary outcomes analyzed in aim 1c.
- Clarified the exploratory measures including the calibrated severity score from the ADOS and the reading the mind in the eyes test.
- Added examination of potential interactions with defined classes of concomitant medications.
- Clarified procedures for flexible dosing and doses labeled by letter.
- Added suicidality assessments to schedule of visits and provided section describing how assessments would be done.

Summary of Changes (Protocol version date: Jan 16 2014)
- Define deafness and blindness
- Duke genetics testing is now NOT optional, but the NIMH samples ARE still optional. Because the Duke samples (mRNA/methylation) are part of our specific/exploratory aims, we did not want to dilute the sample size. With genetics you run the risk of not having enough power because the sample size is too small, so we felt it was important to require this sample to ensure it is collected from all subjects. We will more likely be able to see an effect with a larger sample.
- Changed citations and fixed the reference section as they appear in the text using Endnote.
- Deleted the previous reference list and created an Endnote automatically updated version
- Added clarification that screening labs must be repeated if there is more than 12 weeks between the screening and baseline visits.
- Change the CASI-4R to the CASI-V version
- Taking over psychiatric care for subjects is now optional. This will be determined by site.
- Clarified that unblinding will not be permitted in this protocol. However, subject’s may have treatment interrupted (temporarily discontinued) by treating clinician and the subject may be re-challenged if it is discussed and approved by the SC.
• Addition of a more specific cardiac monitoring plan where heart rate, blood pressure and pulse will be monitored at every visit in addition to clinical parameters in the SLAES. Syncope (fainting) is added as a separate line item in the SLAES.
• Added optional PK protocol (section 12)
• Move methylation sample and plasma/salivary OT sample from month 8 (week 32) to week 36 (month 9) to make it coincide with PK sample for those individuals participating in the optional PK study (i.e., eliminating an additional blood draw for those who are participating in the PK study).
• Updated table of contents
• Clarified in randomization procedures that we will stratify both by functional status and by age group.
• The ABC and PDDBI-SV will be added to all in office visits. The schedule of events and visit descriptions have been edited to reflect this change.
• Section 10.1 changes made in statistical analysis general modeling section.
• Changed all Month to weeks (example, month 1 will now be week 4)
• Removed information about where the drug will be manufactured/compounded as this information will be directly in the IND application to the FDA and not in the protocol.
• Deleted information about specific dosing concentrations (Tables 3a and 3b).
• Added a table that specified total daily dose (broken up into morning and afternoon doses). Does not specify number of sprays/concentration of each dose.
• Removed ADOS calibrated severity score as a potential exploratory outcome measure
• Removed ADOS from week 48
• Increased the number of mLs needed for NIMH optional genetic sample
• Clarified prohibited benzodiazepines in prohibited meds section of protocol.
• Removed medication administration training video for parents
• Added more specific criteria for increasing and decreasing dose:

**Increases in Dose:** Doses may increase if all three of the following criteria are met:
- CGI-I is not a 1 or a 2
- No evidence of clinically significant adverse events
- Parents agree

**Decreases in Dose:** Doses must be decreased if any of the following criteria are met:
- Significant AEs persist for at least 2 weeks or clinician judges it requires immediate adjustment of dose
  OR
- Clinician, parent, participant felt they were doing better on lower dose
  OR
- CGI score of 6 or 7

Summary of Changes (Protocol version date: March 8 2014)
• Clarified information concerning dosing (added two sentences).
• Added missed X marks in CGI-I and SLAES in check boxes in table 6 for week 2 and 26.
• Added further clarification to exclusion criteria for chronic oxytocin treatment (added that chronic is daily intranasal oxytocin treatment of more than 1 month)
• Clarified an ideal time for plasma/salivary oxytocin collection
• Clarified details on the specific salivary oxytocin collection procedure
• Editorial changes removing bullet points and double words.

Summary of Changes (Protocol version date: July 25 2014)
• Added cyberball task at baseline, week 8, week 24, week 32, week 48 and week 72
• Suggested time for NIMH sample of subject to be drawn is week 36 due to the volume of blood collected at other visits.
• Safety labs must be re-drawn if has been greater than 12 months between screening and baseline
• Optional re-draw at baseline of plasma oxytocin, methylation and salivary oxytocin (prior to first dose of study drug) in order for these levels to be an accurate reflection of baseline levels (for subjects who have had a lengthy time between screening and baseline)
• Clarifying that the T0 draw for the PK study is the same as the regular plasma oxytocin level at weeks 36 and 44. Therefore, those participating in the PK study do not ALSO need an additional tube for the plasma oxytocin levels.
• Change inclusion criteria regarding ADOS and ADI-R. Now subjects must have a clinical diagnosis of ASD confirmed either using the Autism Diagnostic Observation Scale (ADOS, Lord et al., 2001) or the Autism Diagnostic Interview-Revised (ADI-R, Rutter, 2003). For subjects who do not meet criteria on either, but the clinician still believes to have ASD, those individuals may be included if the SC agrees.
• Clarified that dosing may only be decreased by 8IU qD increments and increased by 8IU BID increments.
• Dose decrease criteria clarified. Instead of clinical worsening, the criteria now states that dose may be decreased if there are two consecutive CGI-I scores are worse that the preceding two CGI-I scores.

Summary of Changes (Protocol version date: November 17, 2014)
• Methylation and mRNA will be collected at screening, baseline (optional for those who have had lengthy screening periods), week 8, week 24 and week 36
• Stanford Binet and Mullen must be completed within 1 month of baseline (can be completed at screening but must be repeated if not within 1 month of randomization).
• Clarification on prohibited meds: Remeron (mirtazapine) is allowed but tricyclics/tetracyclic antidepressants are now prohibited.
• Clarified that for the Vineland-II, we will be using the parent/caregiver rating form instead of the survey/interview format and we will not be doing the maladaptive behaviors.
• Pregnancy test (urine or serum) for females of childbearing potential must be confirmed as negative within 2 weeks of baseline appointment. This can either be done at a screening visit or can be done at baseline prior to randomization (urine dipstick test).
• Preferred time to collect NIMH repository sample from subject is now at week 48. This is due to the fact that week 48 now has the least amount of blood drawn due to changes in methylation/mRNA sample collection.
• Removed the PDDBI-Full and instead it will be replaced with the much shorter PDDBI-SV and also removed reference to PDDBI-full in the exploratory outcome measures section of the protocol.
• Clarified in the schedule of events superscript 0 beside CGI-S/I. CGI-S at baseline and CGI-S and CGI-I at all other time points.
• Deleted reference to Week 44 regular plasma OT sample in the PK protocol section as it was added erroneously in the previous version.
• Clarified that we will not be doing the gross motor subtest of the Mullen
• Revised dose decreasing criteria
• Clarified in several locations throughout the protocol that there will now be 6 sites instead of 5 sites.
• Added clarification that cyberball task is an additional outcome measure in section 2.2.3.
• Removed estimates of times/year that the monitor will travel to each site. This may be variable depending on the rate of enrollment at each site.
• DSMB will now meet 2 times/year
• The medical monitor will now review all new treatment emergent adverse effects of moderate or greater severity two times a year in order to coincide with the DSMB meetings.
• Alert values for labs and EKGs are determined by site PI and/or site treating physician
• Administrative change: rearranged reportable events section of the protocol (changed section numbers) to be more clear/concise and also added alert lab/EKG values as considered reportable events and must be reported to UNC within 7 days of the sites awareness.
• Addition of a visual analogue scale for treating physician and coordinator to complete at week 0, 12,24, 36, 48 and 72.
• Made additional clarification in the schedule of events about a previous modification regarding labs. Safety labs (glucose, CO2, Cl, K, Na, Creatinine, BUN, AST, ALT, urine specific gravity and pregnancy test) must be redrawn at baseline if more than 12 months has elapsed between screening and baseline visits. Methylation, plasma/salivary oxytocin has an optional re-draw at baseline if there has been a lengthy time between screening and baseline visits.

Summary of Protocol Changes (Version Date: March 2, 2015)
• Clarified the target dose and the efforts to achieve the target dose if at all possible.
• Increased the requirement for duration of treatment with the target dose (from 4 weeks to 7 weeks) to ensure there was full opportunity to evaluate the target dose. Clarified the rules for maintaining a lower dose than recommended by the titration schedule, timing of subsequent dose increases during the titration phase, mandatory and optional dose reductions and increases above the target dose.
• Increased the total dose given at one time from 40/0 IU (1 high dose insufflation and 2 low dose insufflations) to 48/0 IU (2 high dose insufflations) to allow achievement of the total daily target dose with a single administration time.
• Clarified procedures related to interrupting dosing in order to capture primary outcome measures and safety data very close to the time of the last study treatment to increase interpretability of data.
• Added two additional possible doses in schedule (48 IU AM/0 IU PM and 48 IU AM/24 IU PM) as the maximum dose at any time can be 48 IU
• mRNA was initially overlooked and will be part of optional re-draw at baseline which is now reflected in section 6.2 and schedule of events.
• Clarified wording in the Schedule of events.
• Add full urinalysis at all time points when specific gravity is already analyzed.
• Clarified early termination procedures, need to obtain data within 2 weeks of stopping treatment. Specified those ending in blinded phase would complete week 24 procedures and those ending in open label phase would complete week 48 procedures.
• Clarified interrupted treatment procedures
• Add clarification that follow up safety measures may be added based on physician judgment (such as additional unscheduled labs, ECGs, visits etc) in section 6.7
• Changed timing of visual analog scale to correspond with all post-baseline in person scheduled visits (all visits except 2 and 26)
• Clarified that the visual analogue scale (VAS) will be called the VAS of change (not improvement) and will have three sections: overall functioning, repetitive behavior, and social-communicative functioning. Additionally clarified that only the clinician will complete the baseline description of functioning (not the coordinator) and added the VAS to discussion of additional outcome measures.
• Clarified that the Mullen receptive language subtest needs to be done in all children who require ADOS testing with a Module 1 or 2 who are 5 years 8 months old or younger to determine functional strata.
• A focused clinical exam will be done at all post screening visits (instead of full NIMH physical exam form which combines aspects of physical and medical history) and clarified in assessments section that height/weight will be obtained as part of vital signs
• Clarified that medical monitor will review significant and persistent worsening of functioning (CGI-I of 6 or 7) and require the individual participant stop the study.
• Clarifying procedures for re-evaluation visit (if dose is decreased or CGI-I score is 6 or 7).
• Clarifying procedures for when a subject must be withdrawn versus when a subject may be withdrawn.
• Administrative and editorial changes throughout.

Summary of Protocol Changes (Version Date: May 8, 2015; Protocol Version 5.0)
• Revised inclusion/exclusion criteria to allow for all concomitant psychiatric medication that has been stable for 4 weeks prior to baseline appointment.
• Clarified that individual has to be diagnosed with an autism spectrum disorder using DSM-V criteria.
• Removed prohibited medications section

Summary of Protocol Changes (Version Date: June 4, 2015; Protocol Version 5.1)
• Overall PI (Dr. Sikich) is no longer affiliated with UNC-Chapel Hill. New affiliation is with Duke University. Duke University will now be lead site under direction of overall PI (Sikich). Various changes made to clarify this (phone number, email addresses, etc).
Summary of Protocol Changes (Version Date 3/21/2016; Protocol Version 6.0)

• Adding additional exclusion criteria: subjects cannot have active seizures within the 6 months prior to screening or baseline.
• Remove Dr. Hamer as lead statistician.
• Russ Dean is now the PI at the UNC-Data Center
• Clarified that visit procedures may occur on separate days as needed, but open label study drug administration may not occur until all week 24 procedures have been completed.
• Remove cyberball task entirely
• Remove ADI-R at screening, this will be completed at physician discretion only
• Removed the requirement for the IQ testing (Mullen/SB) to be completed within 1 month of the baseline visit. This does not have to be repeated at baseline if it has been more than 1 month between screening and baseline.
• Replace week 2 phone call/email so that the study team only sends the Parent Dose Sheet (schedule B)
• Changed week 12 to only be questionnaires, no in office visit
• Removed ADOS week 24, this may be completed at the physician’s/site’s discretion
• Remove week 26 phone call/email
• Removed week 32, 40 and 44 visits where dose is not expected to change. Subjects will be instructed to contact the site if there are any issues between scheduled visits. Subjects may always have the ability for an unscheduled visit as needed.
• Week 36 visit
  o Remove VABS and RMET
  o Added safety lab collection (blood/urine)
• Remove the following procedures at week 48:
  o Removed EKG
  o Removed the blood draw, urine and saliva collection at week 48 (plasma oxytocin, safety labs, salivary oxytocin) at week 48, it is the physician’s discretion if they want to assess safety labs (blood and urine) only
• Removed week 72 visit
• Added down titration schedule at the end of the study or if a subject early terminates and agrees to follow the down titration schedule
• Added a follow up phone call (SLAES) to be completed after study drug has been stopped at week 53-55
• Shorten early termination visit. No blood/saliva/EKG/ADOS or IQ testing is required at an E/T visit.
• Made general clarifications and better wording surrounding the dosing. Major changes include:
  o For optional dose reductions, clarified that the SLAES does not need to be completed, but adverse events do need to be assessed and documented.
  o Changed criteria for increasing above the target dose: removed criteria that CGI-I cannot be a 1. If the CGI-I is a 1, but the clinician still feels there is room for improvement, then the dose may still be increased above target.
  o Change dosing scheme in open label phase:
    • Week 24-28 = 24 IU TDD
    • Week 28-36 = 48 IU TDD
• Week 36-48 = 72 IU TDD
• General clarifications were made regarding wording surrounding the Parent Dose Sheet and medication diary. No procedures were changed.
• It was clarified that subjects will be given enough study drug to last until their next scheduled visit.
• Clarified that PK visits may occur at any time starting at week 36 or later and clarified the suggested dosing for each of the visits.
• Decreased overall samples size to 290 due to lower than expected attrition rates.
• Adding more wording to clarify definitions for relatedness: Yes= related, likely = probably, no = unrelated
• Added additional definitions surrounding adverse event monitoring related to the SLAES:
  • Pattern Definition: This is to help the clinician define the pattern of the AE and give some clarity to timing of an event.
  • Change/Outcome-This should be captured in order to help the clinician make a clear decision on a severity rating and better follow the AE through time.
  • Action Take-The action taken after the report of an AE can be captured by the definitions below:

15 Literature References


